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I
The resurrection of inactive endogenous retroviruses allows us to learn about
interactions between extinct pathogens and their hosts that occurred millions of years
ago. Two of these paleoviruses, chimpanzee endogenous retrovirus 1 and 2 (CERV1 and
CERV2), are relatives of modern murine leukemia viruses that are found in the genomes
of a variety of old world primates, but are absent from the human genome. The nonexistence of human CERV1 and CERV2 homologues is peculiar given the numerous
apparent cross-species transmissions that occurred between ancestors of old world
monkeys, gorillas, and chimpanzees. It is possible that antiviral proteins were able to
protect human ancestors from colonization by CERV1 and CERV2. Indeed, sequence
analyses of modern primate restriction factors has suggested that these genes have
evolved under positive selection, presumably due to their combat with invading
pathogens throughout primate history. Here we investigate whether TRIM5 and
APOBEC3 antiviral factors were able to restrict the replication of CERV1 and CERV2.
Such an interaction would imply a potential involvement of these proteins in the limited
host range and, perhaps, even the extinction of CERV1 and CERV2. Reciprocally,

activity against CERV1 and CERV2 would suggest that archaic gammaretroviruses
contributed to the positive selection observed in TRIM5 and APOBEC3 genes.
Our analyses suggest that TRIM5" proteins did not pose a major barrier to the
cross-species transmission or contributed to the extinction of CERV1 and CERV2.
However, we uncovered extensive evidence for the inactivation of endogenous
gammaretroviruses by the action of APOBEC3 cytidine deaminases. Both CERV1 and
CERV2, as well as their homologues in the rhesus macaque, bore mutational scars that
are characteristic of APOBEC3 activity. A reconstructed CERV2 Gag was used in vitro
to confirm that APOBEC3G was capable of restricting CERV2 infection. Therefore, it
appears that primate APOBEC3 proteins were capable of targeting ancient primate
gammaretroviruses. It remains possible that APOBEC3 proteins were able to limit the
cross-species transmission and cause the inactivation of these viruses.

II
Although HIV-1 is able to use an antagonist to defend itself from restriction by
APOBEC3 proteins, hypermutation is abundant in vivo. It is currently unclear if
hypermutants have an impact on the evolution of a viral population. The diversity
induced by APOBEC3 may benefit a continually evolving population by providing a
large scope of variability for selection to act upon or, quite the opposite, it may constitute
a deleterious genetic load. The potential impact that APOBEC3-induced hypermutation
can have on a replicating HIV-1 population was studied in vitro. After a period of
growth in T cell lines, an accumulation of hypermutated sequences was observed in an
HIV-1 that lacked the APOBEC3 antagonist, Vif. The resulting viral population

displayed a fitness disadvantage in non-restrictive cells relative to a Vif-proficient virus.
In spite of this apparent genetic load, though, the Vif-deficient virus was capable of
persistent replication. However, unlike the Vif-positive virus, the hypermutated virus
was unable to acquire drug resistance in the presence of nevirapine. Although this result
argues against the notion that APOBEC3-induced variability can accelerate HIV-1
evolution, a small degree of APOBEC3-associated mutations also occurred in the Vifproficient virus and this low-level APOBEC3 activity may have contributed to the
emergence of nevirapine resistance.

III
In order to enter cells, retroviruses must usurp a host cell surface receptor. Viral
receptors can dictate both the cell tropism and host range of the retroviruses that exploit
them. Therefore, the identity of the CERV2 receptor is critical to the study of CERV2
transmissions and endogenizations that took place during ancient primate evolution. To
investigate the CERV2 host range and identify its receptor, we constructed a consensus
CERV2 envelope protein derived using sequences found in the chimpanzee genome.
CERV2 enveloped MLV particles were capable of infecting cell lines from a wide range
of species, including humans. The permissivity of human cells for CERV2 argues against
the notion that human ancestors were protected from CERV2 by the lack of a functional
receptor. Using a Hela cDNA library expressed in CERV2 resistant hamster cells, we
identified copper transport protein 1 (CTR1) as a novel retrovirus receptor that was
presumably used by CERV2 during its exogenous replication more than one million years
ago. Expression of human CTR1 was sufficient to confer CERV2 permissively to

otherwise resistant hamster cell lines, which was accompanied by an increase in virion
binding. The observed increase in hamster cell infection that came with CTR1
expression was specific to CERV2 enveloped virus, with no gain in permissivity to
pseudotypes bearing envelopes from several other gammaretroviruses. Furthermore,
siRNA-induced CTR1 knockdown or CuCl2 treatment specifically decreased CERV2
infection of human cells. We have also identified mutations in highly conserved CTR1
residues that have rendered hamster CTR1 inactive as a CERV2 cell surface receptor,
including a deletion in a copper-binding motif that is largely conserved from humans to
zebrafish. These receptor-inactivating mutations in hamster CTR1 are accompanied by
an increased number of extracellular copper-coordinating residues compared to CTR1
proteins from other species. This apparent compensation may represent an evolutionary
barrier that primates would have had to overcome to avoid CTR1 usage by CERV2 or
related viruses that might have used this protein as a receptor.
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Chapter I. Retroviridae, host proteins, and endogenous retroviruses

The two processes that define retroviruses are the synthesis of a DNA
intermediate from two single stranded RNA genomes, and the subsequent integration of
the viral genome into host chromosomal DNA (1). The presence of provirus in cellular
genomes of the host means that the viral genome will be copied by cellular DNA
replication machinery and then carried forward into progeny cells. The long-term
residence of human immunodeficiency virus (HIV) in target cells, including long-lived
resting CD4+ T cells, is likely to be a primary reason why patients are unable to clear the
virus even during highly active antiretroviral therapy (2-4). Retroviral integration into
the genomes of target cells also allows for the possibility of Mendelian inheritance of
proviruses if their integration occurs in the host germ line (5). This route of vertical
transmission results in an organism-wide establishment of provirus in the genome of
progeny. Such endogenization events have occurred numerous times during primate
evolution and, in some cases, are shared by diverse primate lineages (6-12). Endogenous
retroviruses thus represent a record of ancient retroviral infections and these paleoviruses
can provide us with information regarding past interactions of hosts and pathogens (13).
Retroviruses are categorized into several genera based on their phylogenetic
relatedness (Figure 1). The lentiviruses include HIV and the simian immunodeficiency
viruses (SIV). At least three transmissions of an SIV from chimpanzees (SIVcpz)
resulted in HIV-1; a pathogen whose infection causes acquired immunodeficiency
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syndrome (AIDS) and, according to the World Health Organization, has spread to more
than 60 million people worldwide (14, 15). Lentiviruses are complex retroviruses in that
they encode several small accessory genes in addition to the GagPol and Env genes
common to all retroviruses. In contrast, the lack of accessory genes in
gammaretroviruses classifies them as simple retroviruses. The gammaretrovirus genus
includes the murine leukemia viruses (MLV), feline leukemia virus (FeLV), and gibbon
ape leukemia virus (GALV).

Figure 1. Phylogeny of retroviruses. An Unrooted neighbor-joining tree based on an alignment of
reverse transcriptase amino acid sequences is shown. Adapted from Weiss Retrovirology 2006
(16).

Lentiviruses have rarely been observed to be endogenous in their hosts. The only
known endogenous lentiviruses were identified in the genomes of the European rabbit
and the gray mouse lemur of Madagascar (17, 18). A phylogeny of reverse transcriptase
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sequences and the presence of the Tat and Rev accessory genes suggest that the rabbit
endogenous lentivirus (RELIK) constitutes a unique lentivirus subgroup. The existence
of orthologous RELIK insertions in the European hare suggests that these viruses
replicated before the divergence of the European hare and rabbit from a common ancestor
12 million years ago (19). Phylogenetic analyses using conserved portions of lentiviral
GagPol grouped the gray mouse lemur endogenous lentivirus with the modern primate
lentiviruses and it was suggested that this virus represents an evolutionary intermediate
between the SIVs and ancestral lentiviruses. Importantly, the identification of an SIV in
the lemur suggests that either primate lentiviruses were able to spread in a vector species
capable of traversing water, or primate lentiviruses are as old as the last colonization of
Madagascar by terrestrial mammals 14 million years ago.
Unlike lentiviruses, endogenous gammaretroviruses are common in diverse
mammalian species and these viruses include the porcine endogenous retroviruses
(PERV), feline endogenous retroviruses (RD114 and endogenous FeLV), and a variety of
endogenous MLVs (all discussed in later sections). Gammaretroviruses are also
abundant in primate genomes and, among them, chimpanzee endogenous retroviruses 1
and 2 (CERV1 and CERV2) are the groups most closely related to the modern murine
leukemia virus (8, 9, 20). CERV1 and 2 are of particular interest because, in spite of the
existence of homologues in the genomes of bonobos, gorillas, and old world monkeys,
they are curiously absent in humans. Thus, it appears that both viruses replicated
following the divergence of the human and chimpanzee lineage six million years ago,
with cross species transmissions resulting in endogenizations within diverse old world
primate species, but not in the ancestors of modern humans. It remains possible that a
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genetically encoded protection guarded human ancestors from CERV1 and CERV2
invasion during the time that they were becoming endogenized in the non-human primate
lineages 1.3 to 6.0 million years ago (8). An exploration of such possibilities, though,
warrants an initial discussion of the ways in which retroviral replication depends on some
host factors and is assaulted by others.

Retroviral envelopes and cell-surface receptors
Infection of a cell with a retrovirus particle begins with the interaction of the viral
envelope glycoprotein with a cell surface receptor (Figure 2). The maturation of the
envelope involves furin cleavage during its transport through the Golgi to form a surface
protein (SU) and a single-pass transmembrane protein (TM) (21, 22). SU contains
receptor-binding regions, while TM is responsible for fusion of viral and cellular
membranes. In HIV, trimeric gp120 binds to receptor molecules and sits atop trimeric
gp41 (23), both of which are known to be the target of antibodies that are capable of
neutralizing the virus [reviewed in (24, 25)]. Although monoclonal antibodies have been
isolated whose recognition of antigens on the envelope surface is dependant on
glycosylated residues (26, 27), glycans are likely to generally increase the difficulty in
acquiring antibody recognition of key envelope structures (28). Indeed, mutagenesis at
glycosylated residues generally increases the neutralization sensitivity of HIV-1 envelope
to polyclonal sera (29-31). In addition, evolution by the virus repeatedly allows it to
persist in the face of continual antibody generation by the host (32-34). gp120 contains
five variable loops and sequence flexibility in these regions, along with alterations in
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Figure 2. The retrovirus replication cycle. The left panel depicts steps that take place during
retroviral infection and the right panel describes the production of virus particles. The various
stages of the cycle are referred to throughout this chapter. Taken from Goff Nature Reviews
Microbiology 2007 (35).

gp120 glycosylation, aid the virus in its escape from immune responses (23, 34, 36-39).
HIV-1 cell tropism is greatly limited by the use of CD4 as its receptor, which is
primarily expressed only on helper T-cells, macrophages, and dendritic cells (40). Target
cell range is further narrowed by the requirement for gp120 to also bind to either CCR5
or CXCR4 chemokine receptors (41-44). The identification of two HIV-1 co-receptor
usages largely explained the ability of only some isolates to induce cell fusions (or
syncytia) in laboratory T cell lines, in that the ability to induce T cell syncytia was
associated with CXCR4 usage (45-47). Intriguingly, most transmitted viruses use CCR5
(R5-tropic) and about 50% eventually undergo a shift to CXCR4 usage (X4-tropic) that is
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temporally correlated with disease progression (48, 49). Determinants of this differential
co-receptor usage are largely found in the V3 loop of gp120 (50-55). It appears that the
co-receptor utilized by HIV-1 can dictate which CD4+ T cell compartment it
predominantly infects. Studies in rhesus macaques using a chimeric SIVmac containing
either X4-tropic or R5-tropic HIV-1 envelopes (X4 or R5 SHIVs) have demonstrated that
X4-tropism causes the preferential depletion of naïve CD4+ T cells in the peripheral
blood and in solid lymph tissue, while R5 SHIVs primarily deplete memory T-cells in the
gut (56-58). Further analyses confirmed that biased patterns of infection correlated well
with the depletion of specific cellular compartments.
It remains unclear, though, whether a shift in target cell range during the
emergence of X4-tropism from initial R5-tropism causes disease progression or if, quite
the opposite, the depletion of target cell availability during disease progression forces
tropism change. In either case, there likely exists a selective pressure that prevents or
delays the emergence of X4-tropic variants. Indeed, change from an R5- to an X4tropism during SHIV infection in rhesus macaques have a propensity to occur in animals
with relatively weak immune responses and the resulting X4-tropic viruses typically
display an increased susceptibility to neutralization by both polyclonal and monoclonal
antibodies (59-62). These observations support the notion that immune system
abnormalities are just as likely to be a cause rather than an effect of X4-tropic virus
emergence.
In addition to defining a viral pathogen’s specificity for certain cell types within
an infected host, receptor usage is also crucial to the ability of a virus to transmit between
species. Indeed, cellular receptors are often a primary determinant of gammaretroviral
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host range. In the case of MLV, five groups of viruses exist that each display a particular
receptor usage and host range (termed interference groups) (63). It is thought that two
variable regions in MLV SU that surround a conserved core of !-sheets are responsible
for determining receptor specificity (64-66). Ecotropic MLVs use the mouse cationic
transport protein (CAT-1) for entry and display a strictly murine host range (67). In
contrast, an amphotropic envelope can allow MLV to replicate in cells from a variety of
mammalian species through a shift in their receptor usage to the inorganic phosphate
transporter, PIT-2 (68-70). A variant of amphotropic MLV, 10A1, is able to use both
PIT-2 and the closely related PIT-1, placing it in an interference group that includes
gibbon ape leukemia virus (GALV) and feline leukemia virus (FeLV) group B (71).
Similar to the host range expansion allowed by amphotropic envelope, MLV
recombinants carrying envelopes from xenotropic or polytropic endogenous MLVs are
able to use the xenotropic/polytropic receptor (XPR-1), allowing for distinct host ranges
that are determined by their differing interactions with the same receptor (72-77).
Chimeras of human and hamster XPR1 demonstrated that the third extracellular loop
from human XPR1 allows binding of both xenotropic and polytropic MLV, while the
inclusion the second human extracellular loop results in a receptor that is specific for
xenotropic MLV (78). Although polytropic MLV generally has a broader rodent tropism
compared to its xenotropic relative, some wild mice do express XPR1 proteins capable of
allowing xenotropic MLV infection (79, 80). It is tempting to speculate that the observed
mouse XPR1 variability is the product of selective pressure imposed by MLV.
The determination of species-specific tropism by envelope and receptor
interaction is also a common theme among gammaretroviruses other than MLV. For
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example, it has been posited that mutations in the GALV envelope allowed for an
expansion of zoonotic potential that led to koala retrovirus, an endogenous retrovirus that
continues to replicate exogenously in wild koalas (81, 82). In the case of FeLV and
PERV, both are divided into three groups, each with a distinct receptor usage that
determines particular species tropisms. Interestingly, all FeLV and PERV receptors that
have been identified are transport proteins. FeLV group A is transmitted between felines
using the cell surface receptor, thiamine transporter 1 (THTR-1) (83). Within the new
host, FeLV-B and/or FeLV-C pathogenic variants emerge that, unlike their FeLV-A
predecessor are able to infect canine and human cells. FeLV-B arises through
recombination with endogenous retroviruses and consequently has a receptor usage that
is shifted to feline PIT-1 or PIT-2 and is also capable of using human PIT-1 (84-86).
FeLV-C emerges through a multi-tropic intermediate with point mutations that allow for
infection via a heme export protein, FLVCR1 (87-90). This recurrent shift toward
FLVCR1 usage is associated with red cell aplasia, perhaps a consequence of heme
transport disruption during erythroid progenitor cell development. Porcine endogenous
retroviruses are also divided into three groups with variable receptor usage, two of which
are able to infect human cells and have thus been a major concern to the
xenotransplantation field (91). PERV-A is able to infect human cells through the use of
the gammahydroxybutyrate transport protein, PAR-1, or the riboflavin transport protein,
PAR-2 (92). The PERV-B receptor is currently unknown.
Also in line with the recurring theme of transport proteins as gammaretrovirus
receptors is the use of the sodium-dependent neutral amino acid transporter (ASCT2) by
the baboon endogenous retrovirus (BaEV)/RD114 feline endogenous retrovirus/simian
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retrovirus type D (SRV, including mason-pfizer monkey virus) interference group (9395). BaEV, in addition to human ASCT2 and unlike the other members of its
interference group, is also able to use ASCT1 from humans and mice (96). After the
removal of protective N-linked glycosylations, mouse and hamster ASCT1 become
functional receptors for the entire interference group (97). It should be noted that the
usage of ASCT2 by SRV was likely made possible by an ancient recombination event
between two quite distinct viruses. This hypothesis was prompted by the observation that
reverse transcriptase phylogeny clearly classifies SRV as a betaretrovirus, while analyses
using envelope sequences reveals close relatedness with gammaretroviruses in its
interference group (i.e. BaEV and RD114) (98, 99). This emphasizes that virus
classification that lacks inspection of receptor-binding regions can be misleading when
used to predict receptor usage.
Sequence divergence in receptor binding regions does not necessarily predict that
two viruses use distinct receptors. The HERV-W envelope SU is very distinct from that
of RD114, BaEV, and SRV. Nevertheless, the ability of cells expressing ASCT2 to
readily fuse with cells expressing the HERV-W envelope, syncytin, suggests that HERVW also used ASCT2 as a cellular receptor during its exogenous replication (95, 100).
The observation that syncytin is highly expressed in the placenta led to the hypothesis
that its fusogenicity is responsible for syncytiotrophoblast formation during placental
development. An in vitro model of cytotrophoblast maturation demonstrated that
syncytin and ASCT2 expression co-linearly increase during differentiation and inhibition
of syncytin expression leads to a decrease in cell fusions (101). Also in support of a
cellular function for syncytin is the conservation of the following features among diverse
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ape species and 24 human individuals: LTR promoter activity, splice sites required for an
envelope mRNA, the envelope translational start site, and fusogenic activity (102).

Post-entry events and restriction factor encounters
TM-mediated fusion of the viral and cellular membranes allows the core of the
virus to enter the cytoplasm of the target cell. Following entry, the capsid shell
disassembles and the RNA genome is reverse transcribed to form a double-stranded
DNA. During this time, the virus is susceptible to assault by host factors that are capable
of capsid recognition, and others that act on the viral DNA during reverse transcription.
Fv1 is a mouse gene that is similar to the mouse endogenous retrovirus-L Gag and is able
to cofer strain-specific protection of mice from MLV infection (103-105). MLV variants
displaying an N- and B-tropism, determined by differences in their capsid N-terminal
domain, are resistant to the N and B alleles of Fv1, respectively (106, 107). Although the
exact mechanism of restriction by Fv1 is elusive, it is clear that its capsid-specific action
depends on Fv1 molecules in the target cell that are saturable at high multiplicities of
infection. N-MLV is also sensitive to post-entry restriction by some tripartite motif
(TRIM) 5" proteins (108-110).
TRIM5" is a primate restriction factor that was first recognized for its ability to
form a major block to HIV-1 infection in rhesus macaques (108, 111, 112). Although
human TRIM5" is unable to restrict HIV-1, it is active against N-tropic MLV (108-110).
The species-specific sensitivities of viruses to TRIM5", like Fv1 vulnerability, are
determined by amino acid residues found in the capsid N-terminal domain that are
exposed on the surface of the viral core prior to disassembly (113-115). TRIM proteins
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share homologous RING finger, B-box, and coiled coil domains (116). In addition to this
tripartite motif, TRIM5" also contains a SPRY/B30.2 domain. It has been demonstrated
that the SPRY/B30.2 domain of TRIM5" is responsible for capsid recognition, while the
RING and B-box domains contribute an unknown, but crucial function during restriction
(117-121). Additionally, a coiled-coil domain allows TRIM5" multimerization and can
allow non-functional truncated TRIM" mutants to have a dominant negative effect (121).
The TRIM5" RING finger has been shown to have E3 ubiquitin ligase activity and
induces auto-polyubiquitination, which can affect the half-life of the protein (122, 123).
During restriction, TRIM5" has been observed to undergo proteosome-dependent
degradation (124). The involvement of the proteosome in restriction is unclear, though,
given that treatment of cells with proteosome inhibitors can cause an increase in the
formation of reverse transcription products but are unable to cause an increase in
infection during TRIM5"-mediated restriction (125-128).
A cellular prolyl isomerase is also able to modulate HIV-1 infection. It has been
shown that cyclophilin A (CypA) interacts with HIV-1 Gag and is efficiently incorporates
into virions (129-131). Disruption of CypA packaging with a small molecule
(cyclosporine A) or mutation at a single proline residue in Gag decreased infection in
human cell lines. In later work, though, expression of CypA in target rather than
producer cells was shown to modulate HIV-1 infection and these effects differed
according to both the capsid sequence and target cell line used (132, 133). For example,
cyclosporin A treatment of Jurkat and HOS cells decreased infection. In contrast,
treatment of HeLa and H9 cells did not affect infection with wildtype virus and actually
enhanced infection with virus containing the A92E or G94D capsid cyclophilin A
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resistance mutations (134, 135). Cyclophilin A in the target cell, therefore, has
differential effects on infection depending on amino acid identities on the incoming
capsid. Furthermore, the cell type specificity of these phenomena suggest a possible
involvement of unknown host factors.
A specific linkage between cyclophilin A and restriction factors was demonstrated
by the observation that disruption of its interaction with capsid using cyclosporine A or
siRNA knockdown of target cell cyclosporine A was able to relieve the restriction of
HIV-1 by rhesus macaque TRIM5" (136-138). Thus, it appears that the cyclophilin Acapsid interaction can be crucial to TRIM5" activity. In support of this assertion is the
observation that convergent evolution has produced TRIM-cyclophilin A (TRIMCyp)
fusion proteins in new world and old world monkeys by gene retrotransposition (139144). Recurrent TRIMCyp formation emphasizes the antiviral potential that linkages
between cyclophilin A and TRIM5 activities can offer and, furthermore, suggests that
their combined function has provided primates with crucial protections from retroviruses
throughout history. Additionally, high ratios of nonsynonymous to synonymous mutation
have been observed in primate TRIM5" genes, suggesting that the evolution of these loci
has been driven by positive selection (145, 146). The conclusion that TRIM5" genes
have been under positive selection during primate evolution further suggests that they
were rescuing primates from viral challenge long before the modern infections that we
observe today.
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Figure 3. Reverse Transcription. RNA is represented by red lines and DNA, by thick black lines.
Each step is described in the text. Drawing is by A. Telsnitsky and is taken from Field’s Virology,
Fifth Edition (147).

If the retroviral replication cycle is able to proceed normally, reverse transcriptase
next synthesizes the viral cDNA to be integrated into the cellular genome (Figure 3)
(148-150). DNA synthesis does not commence until after entry into the target cell,
perhaps due to the lack of deoxyribonucleotides in the virion. Virion-packaged cellular
tRNA is usurped for the initiation of reverse transcription at the primer-binding site
(PBS), located just 3’ of the 5’ long terminal repeat (LTR). The 5’ LTR is reverse
transcribed first, forming the minus-strand strong-stop DNA before degradation of the
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first template region by the RNase H domain of reverse transcriptase. The freed strongstop DNA next binds to the opposite end of the viral RNA through complementation with
sequence in its 3’ end, thus allowing reverse transcription and the coupled RNase H
activity to proceed through all open reading frames to the 5’ end of the PBS. RNase H
activity initially spares a polypurine tract (PPT) adjacent to the 3’ LTR and this
remaining RNA serves as a primer for synthesis of the 3’LTR positive strand before
further RNA digestion. A new PBS is synthesized by the reverse transcription of the 5’
end of the tRNA (plus-strand strong-stop DNA) prior to tRNA digestion, again by viral
RNase H. Finally, the DNA-templated completion of both strands is prompted by
circularization via base pairing at the PBS.
The existence of single-stranded DNA intermediates during reverse transcription
leaves the virus vulnerable to attack by already present cytidine deaminases, carried from
the virus-producing cell by the virion itself. The apolipoprotein B mRNA editing enzyme
catalytic polypeptide (APOBEC) protein family of cytidine deaminases includes at least
two restriction factors that are capable of acting potently on retroviruses- APOBEC3G
and APOBEC3F (151-155). APOBEC3B, APOBEC3C, APOBEC3DE, and
APOBEC3H have also been shown to have smaller degrees of antiviral activity (156161). When APOBEC3 is expressed in virus-producing cells, they are incorporated into
budding viral particles through their interaction with the nucleocapsid domain in an
RNA-dependent manner (162-168). Following reverse transcription in the target cell,
APOBEC3 proteins are able to deaminate deoxycytidine residues on the nascent negative
sense cDNA to deoxyuridine (169-171). During synthesis of the DNA positive strand,
the presence of aberrant deoxyuridine results in guanosine to adenosine mutation.
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APOBEC3-induced cytidine deamination takes place with biases toward specific
dinucleotide contexts. APOBEC3G prefers cytidines immediately 3’ of another cytidine,
which results in GG to AG mutations; while the other APOBEC3 proteins deaminate
cytidine in a TC dinucleotide context and these events cause GA to AA mutations
(APOBEC3G can also cause GA to AA mutations but far less often than GG to AG
mutations) (153-155, 160, 161, 170, 171). The frequency of hypermutation can vary
across the viral genome according to the length of time that single-stranded DNA is
exposed prior to complementation to nascent positive-strand DNA (171). In HIV-1, this
variability manifests as two gradients with increasing G to A mutation frequency in the 5’
to 3’ direction that peak just 5’ of the polypurine tracts (172).
Human APOBEC3G was first identified as a restriction factor when it was found
to determine the permissivity of cell lines to HIV-1 virions that lack the Vif protein
(HIV-1 deltaVif) (152). Vif is able to inhibit APOBEC3G by recruiting it to a cullin5/E2 ubiquitin ligase complex. This results in the polyubiquitination and subsequent
proteosomal degradation of APOBEC3G before it can be incorporated into the budding
virion (173, 174). The ability of Vif to inhibit APOBEC3 proteins varies in a speciesspecific manner (156). HIV-1 Vif is not able to induce the degradation of rhesus
macaque APOBEC3G or APOBEC3F and this, in part, explains the inability of HIV to
infect these animals (155, 175). The APOBEC3 gene family has expanded from one
gene in mice to seven genes in primates and the primate genes, including APOBEC3F
and APOBEC3G, have been under strong positive selection since before the divergence
of old and new world monkeys 33 million years ago (176, 177). Therefore, it appears
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that, like TRIM5 proteins, APOBEC3 provided a critical defense in primates against
retroviruses long before the activities we observe today against modern viruses.
The restriction of Vif-deficient HIV-1 by APOBEC3F/G could take place through
several possible mechanisms. First, the amount of proviral DNA is decreased during
restriction (178, 179). This could be the result of the removal of uracil from
deoxyuridine by uracil DNA glycosylase (UNG), followed by the action of cellular
DNases. Indeed, UNG-2 is incorporated into virions but a depletion of UNG-2 in virusproducing cells is not able to rescue HIV-1 from restriction, leaving this mechanism
unsupported (180). It has also been proposed that APOBEC3F- and APOBEC3Gmediated restriction may be independent of deaminase activity (181-184). APOBEC3F
and APOBEC3G mutants containing changes to their C-terminal zinc coordinating
catalytic site were not competent as deaminases but still retained at least 60% of their
antiviral activity. Contrary to this, it had already been shown that mutating these same
sites does destroy the antiviral activity of APOBEC3G (169). Furthermore, it has been
argued that any deaminase-independent restriction observed is only made possible by in
vitro over-expression of APOBEC3G, as evidenced by a complete lack of restriction
capability in deaminase-deficient mutants when their expression levels are comparable to
APOBEC3G expression in activated peripheral blood mononuclear cells (PBMC) (185187). Although the in vivo applicability of a deaminase-independent restriction of HIV-1
by APOBEC3G remains controversial, a variety of mechanisms have been proposed
including inhibition of tRNA priming, strand transfer, both early and late viral DNA
production, and integration (188-191).
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Perhaps the most intuitive explanation for the antiviral effects of A3 proteins,
though, is a debilitation of viral progeny by G to A hypermutation in the provirus. This is
especially likely in the case of APOBEC3G mediated restriction, which due to the bias in
the dinucleotide context of APOBEC3G-triggered deamination, has a propensity to cause
tryptophan codons (UGG) to mutate to stop codons (UAG). When both mutated
dinucleotide contexts are considered, the high degree of hypermutation found in
individual proviruses would likely impact their fitness through frequent nonsynonomous
mutations.

Hypermutation in vivo
Investigations into the effects of hypermutation on HIV-1 are directly applicable
to HIV evolution within an infected individual because, in spite of Vif activity,
hypermutation does occur in vivo. Janini et al. analyzed protease genes integrated in
peripheral blood mononuclear cells (PBMC) from patients at different disease stages and
infected with a variety of HIV subtypes (192). Abundant hypermutated protease
sequences were detected in 43% of the 53 patients studied. In the hypermutated
sequences, 20 to 94% of G residues in the GG and GA dinucleotide contexts were
mutated to A, which is consistent with APOBEC3G and APOBEC3F activity,
respectively. Mutations in the GA context were twice as frequent as mutations in the GG
context suggesting that APOBEC3 proteins other than APOBEC3G may predominate in
HIV-1 hypermutation in vivo. Consistent with this hypothesis is the observation that
HIV-1 Vif is less efficient at triggering APOBEC3F degradation compared to
APOBEC3G degradation (155).
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In another study, Kieffer et al. searched for hypermutated RT and protease
sequences in both plasma virus and resting CD4+T cells (193). Plasma virus and PBMC
were isolated from nine patients and the PBMC was fractionated to isolate resting CD4+T
cells. The patients had a undetectable viremia due to suppression by highly active
antiretroviral therapy (HAART). Resting CD4+T cells were studied because even when
viremia is kept at low levels by HAART, integrated latent viral proviruses remain
abundant in these cells. There were no hypermutated sequences detected in plasma
virus; but in the case of resting CD4+T cells, at least one hypermutated sequence was
found in each patient. The hypermutation was manifested as G to A changes with 98% of
these changes occurring in the GA or GG dinucleotide context. Unlike the study
conducted by Janini et al., mutations within the GG context were four times more
common than mutations within the GA context. Perhaps the use of resting CD4+T cells,
as opposed to unfractionated PBMC, from patients on successful HAART narrows the
study to a latent pool containing inactive hypermutated proviruses that have primarily
been mutated by APOBEC3G. In support of this assertion is the observation that
APOBEC3G is more active against HIV delta Vif than APOBEC3F and has a greater
propensity to induce stop codons (155). Additionally, APOBEC3G has been observed in
cell culture experiments to be capable of causing a small amount of GG to AG mutations
in HIV sequences, even in the presence of Vif (194).
Overall, it is unclear which APOBEC3 protein(s) are predominately active against
HIV in vivo. The preferred dinucleotide context of G to A mutations may vary greatly
within a single patient. It is likely that the ability of each deaminase to hypermutate HIV
depends on the potency of the Vif species encountered. It has been shown that a variety
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of single amino acid changes in Vif can affect its specificity for APOBEC3F,
APOBEC3G or both (195, 196). A study by Simon et al. described highly variable Vif
sequences within individual patients and inactive Vif genes were isolated from all seven
patients studied (197). Furthermore, Vif genes were isolated that were active against
APOBEC3F and APOBEC3G, APOBEC3F but not APOBEC3G, or vice versa.
Concordantly, the predominance of either GG to AG or GA to AA substitutions varied
between hypermutated proviruses. This suggests that Vif variability can allow for a large
range in both the quantity and the dinucleotide context of hypermutation in vivo.
Aside from the generation of stop codons by APOBEC3G activity, any increase in
the amount of random mutation could be very deleterious to the overall fitness of an
HIV-1 population. It has been argued that HIV-1 reverse transcriptase has evolved a
fidelity high enough to maintain sufficient sequence integrity, but low enough to allow
rapid sequence diversification (198). An increase in the frequency of random mutations
may push the mutation rate high enough to allow the accumulation of a significant
number of deleterious mutations, thus giving rise to a genetic load with significant
impacts on the overall population fitness.
On the other hand, the ability of HIV reverse transcriptase to generate
recombinant genomes could allow for the continual regeneration of fit viruses despite the
generation of hypermutants. Recombination in retroviruses is possible because it is an
inherent trait of retroviral virions to contain two viral genomes (199-201). When virus is
produced from a cell containing multiple infections, packaging of homologous RNA from
more than one proviral source can occur. This results in the presence of differing
templates for reverse transcription during the subsequent infection. It appears that
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reverse transcriptase is capable of jumping between templates multiple times during a
single cycle of replication (202, 203). The resulting viral DNA that continues on to
integration is, thus, a recombinant of the two genomes used during reverse transcription.
It has long been theorized that recombination has repeatedly arisen throughout biology, in
part, to ameliorate the effects that a load of deleterious mutations can have on a
population (204-207). It is possible that it is the high frequency of recombination in
HIV-1 that allows it to cope with high mutation rates and, perhaps, even make use of the
variability that hypermutation offers. Recombination between hypermutants and
genomes untouched by deamination may generate fit viruses containing a relatively lowlevel of APOBEC3-induced mutation.
Mutations that resemble those imposed by APOBEC3 proteins (i.e. G to A within
GG or GA contexts) have been observed in viruses that have a low burden of mutation
compared to proviruses that have been crippled by hypermutation (208-210). Low levels
of putative APOBEC3-induced mutation were shown to include residues within
confirmed cytotoxic T lymphocyte epitopes that evolved rapidly during early infection
(210). This suggests that variability generated by APOBEC3 activity can be utilized by
HIV-1 during immune evasion. Furthermore, the occurrence of drug resistance mutations
within sequence contexts targeted by APOBEC3 suggests that hypermutation also has the
potential to contribute to drug resistance evolution (reviewed in Chapter IV). APOBEC3
activity in vitro has been shown to induce the emergence of 3TC escape mutants, though
this required the cloning of hypermutated loci from unfit variants into wildtype virus
(211). It is possible that this recapitulated recombination events that can occur between
replication competent virus and inactivated hypermutants in vivo. So, the question arises
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for a viral population within an infected host: is hypermutation induced by APOBEC3 a
burden or a benefit?

Post-reverse transcription events and production of viral progeny
Following reverse transcription, the newly synthesized viral DNA transports to
the nucleus as part of a pre-integration complex that includes integrase, reverse
transcriptase, and Gag components (212, 213). The biochemical steps of integration have
been extensively studied in vitro [reviewed in (214) and Figure 4]. First, integrase
transforms the blunt ends of the provirus into 5’ overhangs by the removal of two
nucleotides, typically TT, leaving recessed strands ending in CA. Second, the newly
formed 3’ hydroxyls each undergo a nucleophilic attack of phosphorous in the cellular
DNA. The resulting transesterification generates single-stranded nicks between the 5’
end of each proviral DNA strand and the displaced 3’ ends of the cellular DNA. Two
nucleotides at the free 5’ ends of viral DNA and several cellular nucleotides on the
opposite, ligated strand lack base pairing. These structures are promptly repaired, likely
by cellular machinery, with the insertion of nucleotides that are complementary to
unpaired cellular sequence followed by a final transesterification that replaces the two
unpaired viral nucleotides and removes the nick.
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Figure 4. Retroviral integration. The steps involved in the formation of provirus are shown.
These include processing of the viral DNA ends by integrase, nucleophilic attack of cellular DNA
phosphorous atoms by 3’ hydroxyls on the viral DNA (or ‘strand transfer,’ also catalyzed by
integrase), and finally repair single-stranded nicks. Adapted from Goff, Ann. Rev. Gen. 1992
(214).

With the aid of cellular factors, the integrated provirus is now available for both
gene expression and inheritance by cellular progeny. The integrated viral LTR contains
promoter elements that prompt transcription by the cellular RNA polymerase (215-217).
In the case of HIV-1, the viral Tat protein stimulates transcription through the association
of a cyclin T/CDK9 complex with the viral TAR RNA nascent transcript (218-228). This
results in hyperphosphorylation of the RNA polymerase II C-terminal domain and,
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consequently, transcript elongation (225-228). Full-length viral transcripts are capped,
poly-adenylated, and exported for either virion packaging or translation of Gag and
GagPol. Other transcripts are spliced for envelope translation and during the production
of complex retroviruses, alternative splicing allows for the expression of several
accessory genes (229). In HIV-1, the export of intron-containing transcripts requires the
binding of the virus-encoded Rev protein to Rev-responsive elements in the RNA (230236).
Translation of unspliced mRNA produces both Gag and GagPol proteins. The
inclusion of Pol on 5-10% of Gag proteins occurs when structured RNA components in
the transcript cause the ribosome to “ignore” the Gag stop codon. In some retroviruses
(e.g. gammaretroviruses) a tRNA is utilized at the stop codon, while in other viruses (e.g.
lentiviruses) slippage of the ribosome causes a frame shift (237-239). The Gag and
GagPol proteins accumulate on viral RNA at the plasma membrane to form nascent
virions (240-242). Fission of viral and plasma membrane allows assembled particles to
bud from the cell surface. The membrane manipulations required for such an event are
catalyzed by cellular class E vacuolar sorting machinery, which are proteins that
normally execute the topologically similar formation of multi-vesicular bodies [reviewed
in (243, 244)]. Recruitment of class E machinery requires Gag amino acid motifs, termed
late-budding domains (PT/SAP, LYPxL, or PPxY). Finally, processing of Gag and
GagPol by the viral protease facilitates maturation of the budded particle (245, 246). Gag
and GagPol cleavages produce mature matrix, capsid, nucleocapsid, protease, reverse
transcriptase, and integrase proteins.
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Following the budding of a new virion, and before escape from the surface of the
very cell that produced it, the virus may be assaulted by the cell through the action of the
tetherin protein. Tetherin was identified as a host restriction factor based on both its
interferon induction and specific expression in cells that were non-permissive to
replication of HIV-1 lacking expression of the Vpu accessory protein (247, 248).
Biochemical characterization and the replacement of tetherin components with analogous
protein structures have demonstrated that tetherin accomplishes restriction through a
direct bridging of virions to cells, with one end of tetherin attached to the viral membrane
and the other to the plasma membrane (249). Importantly, in the absence of specific
antagonism, tetherin seems to act broadly against enveloped viruses without any
identified protein specificity (250).

Endogenous retroviruses and the lessons that they can offer
We refer to the cycle of extracellular virion production and subsequent cellular
infection as exogenous virus replication. There is utility in such a designation because
the mere presence of provirus in cellular genomes also allows for its replication by the
cell’s indiscriminate DNA polymerase. Such endogenous replication dictates that any
descendent of an infected cell will contain a copy of the integrated provirus. Robin
Weiss first pointed out that heritable elements in cells from chickens were capable of
allowing the replication of Rous sarcoma viruses (RSV) that were normally incompetent
without the aid of a helper virus (5). Later Weiss and Peter Vogt were able to use
carcinogens to induce the release of avian tumor viruses from uninfected chicken cells
(251). These pivotal observations, in combination with the observed heritability of some
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avian leukosis virus (ALV) antigens (252), led to the theory that retroviruses are capable
of invading the host germ line and can consequently become endogenized into the
organism-wide genome of progeny.
Sequencing of primate genomes has expanded our appreciation for retrovirus
endogenizations that have taken place during our own evolution. At least 8% of human
genomic sequence is the result of retroviral infections (253). Genomic sequence,
therefore, provides an ancient historical account of past retroviral epidemics.
Experiments with human endogenous retrovirus K (HERV-K), a virus that was
repeatedly endogenized in the ancestors of modern primates for millions of years,
demonstrated that our understanding of ancient viruses does not have to end with their
sequencing (13, 254). A consensus of inactive human-specific HERV-K integrations was
constructed and gave rise to infectious virus particles in vitro. The virus, perhaps not
produced for over one million years, was further characterized as being resistant to
TRIM5 and APOBEC3G restriction factors, but sensitive to human APOBEC3F. It may,
therefore, be the case that members of the HERV-K family contributed to the positive
selection imposed on the APOBEC3F locus over the course of its evolution. These initial
endeavors in “paleovirology” began to demonstrate the potential that such studies have in
describing the long-term co-evolution of hosts and retroviruses.
The work described herein, sought to extend the exploration of ancient viral
challenges to include primate gammaretroviruses. A comparison of the chimpanzee
genome with our own revealed that there were distinct differences in our retroviral
encounters since the divergence from a common ancestor six million years ago (8, 9). In
fact, 7% of chimpanzee-human INDEL variation is attributable to retrovirus integrations.
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A close relative of the modern MLV, CERV2, and a more distant relative, CERV1, are
present in the genomes of chimpanzees (Figure 5) and other non-human primates, but are
entirely absent from the human genome (8, 9, 20). Therefore, CERV1 and CERV2 may
reveal genetic factors that have influenced cross-species transmissions over the course of
chimpanzee and human speciation. Furthermore, such investigations could support a
notion that a broad repertoire of retroviruses has imposed selective pressures that have
shaped the evolution of modern host factors.
First, we asked whether host factors that restrict modern retroviruses were able to
target CERV1 and CERV2 during their exogenous replication (255). Due to the close
relatedness of CERV1 and CERV2 with moloney MLV, we were able to construct
functional recombinants containing CERV1 or CERV2 capsid N-terminal domains within
an MLV GagPol context. The resulting chimeric virions were shown to be largely
resistant to restriction by human, chimpanzee, and rhesus macaque TRIM5". Therefore,
we cannot speculate that TRIM5" was involved in a protection of human ancestors from
CERV1 or CERV2 infection. An inspection of CERV1 and CERV2 sequences, though,
revealed scars likely made by APOBEC3G. Namely, G-to-A mutations were observed
with bias toward GG dinucleotides. Homologues in the rhesus macaque carried G to A
mutations with both GG and GA dinucleotide contexts implying encounters with multiple
APOBEC3 proteins. Further work in vitro demonstrated that APOBEC3G is capable of
restricting infection by virions carrying CERV2 structural proteins. APOBEC3 proteins
were therefore likely to be capable of restricting these viruses and, in return, infections by
them may have contributed to the positive selection imposed on APOBEC3.
Furthermore, debilitating APOBEC3-induced mutation is likely responsible for the
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Figure 5. Phylogeny of chimpanzee endogenous retroviruses (CERVs). The unrooted neighbor
joining tree is based on CERV reverse transcriptase sequences and those from several
representative retroviruses as indicated. Three classes of endogenous retroviruses are designated:
class I is related to modern gammaretroviruses, class II is related to modern betaretroviruses
(class II CERVs are homologous to HERV-K), and class III is distantly related to modern
spumaviruses. An enlarged portion is shown to indicate the position of CERV1, CERV2, and
MLV on the tree. Adapted from Polavarapu et al. Genome Biology 2006 (8).
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inactivity of many of the individual proviruses. This work allows us to speculate about a
role of APOBEC3 proteins in limiting exogenous replication of these viruses.
The potential impacts that APOBEC3-induced mutation can have on an evolving
population were studied using HIV-1 in vitro. Virus was allowed to replicate in the
presence of varying degrees of APOBEC3 activity. It was evaluated whether the
resulting hypermutation was capable of accelerating drug resistance evolution or if it
constitutes a genetic load that hinders the emergence of escape mutants. Populations of
HIV-1 delta-Vif that carried significant genetic loads were not observed to acquire drug
resistance, even when challenged in fully permissive cells. A low level of APOBEC3associated mutation was also observed in Vif-positive virus and this modest degree of
diversity did not impede and may have contributed to its evolution.
To extend our understanding of host factors that did not assault, but rather aided
CERV2 during the time that it replicated, we constructed a functional consensus envelope
gene. MLV particles carrying this envelope displayed a broad species tropism in tissue
culture and were further used in a genetic screen that identified copper transport protein 1
(CTR-1) as a novel cell-surface receptor that was used by CERV2 during ancient times.
The only species tested that was non-permissive to CERV2 was the hamster and its lack
of permissivity can be explained by subtle differences in CTR1. The identity of the
CERV2 receptor does not predict a limited primate host range. This work does
demonstrate, though, that reconstructions of ancient envelope genes can allow the
discovery of host proteins that have been used as viral receptors throughout evolutionary
history.
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Chapter II. Materials and Methods

Virions and cell lines
Production of virions was accomplished by polyethyleneimine (PEI)
cotransfection of 293T cells. A three-plasmid system was used to generate virus particles
that were only capable of a single cycle of replication. Two scales are described for
production in either 24-well or 100mm dishes. The transfections included plasmids
expressing moloney murine leukemia virus GagPol or HIV-1 GagPol from the NL4.3
laboratory-adapted strain (500ng or 6!g); a vector containing an MLV or HIV-1
packaging sequence proceeding a reporter gene and/or a selectable marker (500ng or
6!g); and an envelope glycoprotein from either vesicular stomatitis virus (VSV) for its
high infectious titer in a broad range of target cells (100ng or 1!g), or a retroviral
envelope as indicated in the text (500ng or 6 !g). The reporter vectors used were CNCG
(256) and CSGW (257), which are MLV and HIV vectors, respectively, that both contain
an eGFP expression cassette.
Plasmids were mixed in serum-free DMEM (50µL or 1mL) followed by addition
of 4µg PEI per 1µg of total DNA (from a 1µg/µL PEI stock solution). This mixture was
vortexed briefly and incubated at room temperature for 10 minutes before addition to
293T cells, which were 60-80% confluent in freshly added media (500!L or 5mL).
Transfections were allowed to proceed overnight before a change to fresh media (500!L
or 8mL). Supernatants were collected 48 hours post-transfection and purified through
0.22!m filters. All infections were allowed to proceed overnight and 5!g/mL polybrene
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was included on all cells except CHO-PGSA. A detailed description of MLV particles
containing endogenous capsid N-terminal domains can be found in a separate section
below.
The LMN8iresZeo cDNA plasmid library was a gift from Stuart Neil and was
generated as follows. Total RNA was extracted using Invitrogen TRIzol from 5x106
HeLa, purified with two sequential chloroform extractions, precipitated in isopropanol,
and washed in 70% ethanol. mRNA was purified from total RNA using Qiagen Oligotex
polyA+ resin. cDNA containing SfiI sites was synthesized and amplified using Clontech
SMART primers and Invitrogen size exclusion columns were used to dispose of small
fragments. Following precipitation and SfiI digestion, cDNA was ligated overnight to
LMN8iresZeo (an MLV vector with a zeocin resistance gene translated via an internal
ribosomal entry site). To assess library complexity, 10% of the ligation was transformed
and serial dilutions were plated. The remaining ligation was transformed and grown
under selection in soft agar for 72 hours.
Virus stocks used to transduce CHO-PGSA cells with the HeLa cDNA library
were titrated by infection of 105 CHO-PGSA cells per well on 12-well plates with a 5fold serial dilution of virus. The following day, infected cells were re-plated on 100mm
dishes and 200!g/mL zeocin was added that evening. Cell foci were counted 10 days
later to determine the number of infectious units per unit volume of the virus stock
solution (IU/mL). An MLV vector expressing a neomycin resistance gene under a CMV
promoter (CN) was used to generate CERV2 enveloped particles for the first round of
library screening. CN was constucted by the removal of CMV-DsRED from CNCR
using BstBI/NotI, followed by klenow treatment and blunt-ended ligation. CERV2
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enveloped virions carrying CN or LHCX (a Clontech MLV vector expressing a
hygromycin resistance gene) were titrated on HeLa cells using 1!g/mL G418 or
100!g/mL hygromycin, respectively, in a fashion similar to the cDNA library titration.
CHO, PGSA, and all derivatives were cultured in ham’s F12 media supplemented
with 10% fetal bovine serum and 1mM glutamine. Pan troglodytes verus skin fibroblasts
AG06939 (Coriell) were grown in MEM alpha with 20% fetal bovine serum and 2mM
glutamine. MT2 and CEMSS cells were grown in RPMI with 10% fetal bovine serum
and 2mM glutamine. All other cell lines were grown in DMEM supplemented with 10%
fetal bovine serum. All media was supplemented with 10!g/mL gentamycin. The CHOCTR1 and PGSA-CTR1 cell lines were generated by cloning CTR1 into LNCX2 (a
Clontech MLV vector containing an LTR-driven neomycin resistance gene and a
multiple-cloning site proceeded 3’ of a CMV promoter) or LNCX2 constructs containing
an HA tag before or after the multiple-cloning site using XhoI and NotI (forward primer:
5’- TATATACTCGagATGGATCATTCCCACCATATGG -3’ reverse primer: 5’TATATAGCGGCCGCTCAATGGCAATGCTCTGTGATATCC -3’). In the case of
CTR1 mutant constructs, PCR products were first cloned using XhoI and NotI into
PCR3.1 (Invitrogen) containing an HA tag sequence 5’ to the cloning site and then
subcloned to LNCX2 using SnaBI and NotI. Hamster CTR1 was amplified from CHO
cDNA using primers designed against untranslated regions that are conserved between
mouse and rat CTR1 (forward primer: 5’TATATACTCGagGGGATCCAGTTCTGagAGGAAGAC -3’ reverse primer 5’TATATAGCGGCCGCAGACAGGagAGagRAGGGATGATTGG -3’). Following
XhoI/NotI cloning into pCR3.1 and sequencing, primers were designed to amplify only
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the open reading frame of hamster CTR1 (forward primer: 5’TATATACTCGagATGGGGATGAACCATATGGGC -3’ reverse primer 5’TATATAGCGGCCGCCTTAATGGCAATGCTCTGTGATGTCC -3’) and this product
was cloned into LNCX2 using XhoI and NotI. VSV-G enveloped MLV pseudotypes
were used to transduced CHO or PGSA cells prior to selection with 1mg/mL G418.

Full-length HIV-1
A pNL4.3 HIV-1 provirus that lacked Vpr expression due to both a start codon
mutation and the introduction of a stop codon (both silent in the Vif open reading frame)
was provided by Stuart Neil. Vif expression was disrupted in this construct by the
introduction of both a 13-nucleotide deletion and an in-frame stop codon to the region
immediately following the end of the GagPol open reading frame. This was done by the
amplification of a region from the AgeI restriction site in Pol to the border of the Vif
deletion and a second region from the end of the Vif deletion to the EcoRI restriction site
in Vpr. The primers were designed to generate products that contained a 29 nucleotide
overlapping sequence that included the introduced Vif mutations (sense primer: 5’GTAAAACACCATATGAAGCTTAGGACTGGTTTTATAGAC -3’ and antisense
primer: 5’- CCAGTCCTAAGCTTCATATGGTGTTTTACTAATCTTTTCCATGTG 3’). Following an overlapping PCR that included the products of the first PCRs as
templates and external primers, the final PCR product was gel-purified and cloned into
the parental pNL4.3 delta Vpr using AgeI and EcoRI. Next, in order to acquire an eGFP
reporter, SalI and SpeI were used to sub-clone both the deltaVpr and deltaVpr/deltaVif
genotypes into an HIV-1 proviral plasmid that expressed NL4.3 GagPol, HXB-2
32

envelope, and eGFP in place of Nef (previously derived from pNL/HXB and R7/3/GFP
(258, 259)). Virus stocks were generated by PEI transfection of 293T cells on 100mm
dishes using 5µg of proviral plasmids. The resulting viruses are referred to in the text as
Vif+ and #Vif.

Endogenous capsid sequence retrieval
To identify MLV-related viruses in primate genomes, the amino acid sequence of
the capsid N-terminal domain of moloney murine leukemia virus was used in a
TBLASTN search of the chimpanzee genome (http://www.ensembl.org). After retrieving
all complete TBLASTN hits, the sequences were separated into two families,
corresponding to CERV1 and CERV2, according to sequence homology and length.
After removing redundant sequences, ClustalW was used to obtain nucleotide and amino
acid consensus sequences for both CERV1 and CERV2 capsid N-terminal domains (CANTDs). The same method was used to find homologues of CERV1 and CERV2 CANTDs in Macaca mulatta (RhERV1 and RhERV2, respectively). RhERV1 CA-NTDs
included two phylogenetically distinct subgroups, termed RhERV1a and RhERV1b, and
two independent consensus sequences were derived. Similarly, CA-NTD sequences from
enMLV were retrieved from the C57BL/6J genomic database. A phylogeny was
reconstructed for all capsid NTDs using ClustalX1.8 and phylogenetic trees were drawn
using Figtree.
Individual CA-NTD amino acid sequences were used in TBLASTN searches and
regions positioned immediately 3’ to precise hits were inspected for Env-like sequences.
The moloney MLV was used to assist in the definition of a theoretical
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CERV1/CERV2/RhERV1/RhERV2 open reading frames. To define a consensus
envelope sequence for each endogenous retrovirus family, a single envelope amino acid
sequence was used as a TBLASTN query. All resulting envelope sequences were aligned
to derive a consensus sequence, regardless of their linkage to a previously retrieved
capsid sequence. Analyses of the CA-linked envelope genes were then performed as for
the CA-NTD sequences. In the case of RhERV2, two distinct groups of envelope
sequences were observed and separate alignments and consensus sequences were derived
for each subgroup of envelopes. Similarly, three distinct enMLV envelopes were
grouped according to the previously defined tropisms of these viruses: polytropic,
modified polytropic, and xenotropic (72). In the case of CERV1, because of the large
numbers of unique CA-NTD sequences, the analysis was confined to two groups of 10
CA-NTDs that were each used to define linked Env sequences. One CA-NTD group had
zero or one G to A mutations, and a second group had "4 G to A mutations.
Because of the small number of CERV2 integrations in the chimpanzee germ line,
all CERV2 proviral sequences were compiled. Flanking regions 1500 nucleotides 5’ and
8000 nucleotides 3’ to the capsid NTDs were aligned. Four of the proviruses aligned for
8293 nucleotides with pairwise identity scores of at least 83%. Therefore, those portions
of sequence were trimmed and defined as full length CERV2 provirus. Six additional
incomplete proviruses were defined. One database derived proviral sequence was
excluded because a 99.9% sequence identity with another locus made it unlikely to be an
independent retroviral integration, and is instead likely to be either a genomic duplication
or an error in the compiling of genomic sequence.
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Generation of endogenous retrovirus CA-NTD/MLV chimera libraries
A library of chimeric GagPol plasmids was generated that contained MoMLV
GagPol with the capsid NTD replaced with that from endogenous retroviruses. Genomic
DNA was isolated using standard protocols from Pan troglodytes verus skin fibroblasts
AG06939 (Coriell), Macaca mulatta 221 cells, and NIH 3T3 cells and used as PCR
template. Primers were designed to anneal to the capsid NTD consensus sequences
described above. Because of relatively high conservation at the 3’ end of the capsid
NTD, the same reverse primer was used for all endogenous retrovirus families: 5’TACYTTRGCCAAATTRGTRGG -3’. The 5’ primers were specific to each virus
family and all contained a BsmI restriction site: CERV1: 5’CTCGCAGGCATTCCCCCTTCGGGAAATAGG -3’; CERV2: 5’CTCGCAGGCATTCCCCCTCCGCACCGTG -3’. To amplify capsid genes from the
Rhesus macaque and mouse genomes, primers were designed to anneal to a p12 region
immediately 5’ of the capsid- RERV1a: 5’CAGCYGCCTGACTCYAYGGTGGCATTCCCCCTT -3’; RERV1b: 5’CRACTCCCTGACTCCACYGTGGCATTCCCTCTC -3’; RERV2: 5’CCTTCYACTTGGCAATCCTCGGCATTCCCCCTC -3’; and enMLV: 5’GCRGAYTCCACCWCCTCYCRGGCATTCCCACTC -3’. A small fragment was
amplified from MLV GagPol using the reverse complement of the capsid NTD 3’ primer:
5’- CCYACYAATTTGGCYAARGTA -3’; and a primer annealing in the MLV capsid
C-terminal domain: 5’- CTTCTAACCTCTCTAACTTTCTCC -3’. The amplified
portion of the MLV GagPol plasmid was engineered to contain an AfeI restriction site.
Thereafter, an overlapping PCR product was generated that included the amplified
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endogenous virus capsid NTDs and the MoMLV capsid CTD fragment. This PCR
product was cloned into the MLV GagPol plasmid using BsmI and AfeI restriction
enzymes. The resulting chimeric GagPol plasmids were isolated and screened for
functional capsid genes by cotransfection with an MLV-based vector containing GFP and
VSV-G envelope using polyethyleneimine (PEI) in 293T cells. Supernatant from these
cells were used to infect hamster CHO-KI-derived cells. Two days post-infection, cells
were trypsinized, fixed in 2% PFA and subjected to FACS analysis using a Guava
Easycyte to determine the percentage infected (GFP-positive) cells. To measure
TRIM5", TRIMCyp and Fv1 sensitivity, Mus dunni tail fibroblasts (MDTF) or MDTF
stably expressing human TRIM5", chimpanzee TRIM5", rhesus macaque TRIM5",
African green monkey TRIM5", owl monkey TRIMCyp, Fv1N, Fv1B, or Fv1NB that have
previously been described (108, 121) were infected in the presence of 5µg/mL polybrene.
GFP-positive cells were quantified by FACS analysis two days post-infection.
To determine whether the E91K mutation in the RhERV2 CA-NTD modulates its
sensitivity to human and chimpanzee TRIM5", this point mutation was introduced by
PCR into a chimeric MLV GagPol plasmid containing a consensus RhERV2 CA-NTD
sequence. Additionally, to determine whether the CA-CTD altered CERV1 sensitivity to
TRIM5", a CERV1 CTD sequence, as described in Kaiser S.M. et al. (260), was
synthesized using as series of overlapping ~60 nucleotide oligonucleotides. The resulting
product was then used in an overlapping PCR reaction with the CERV1 CA-NTD
consensus sequence and this full-length capsid was cloned into the MLV GagPol
plasmid. In order to match the CERV1 CA-NTD consensus to the ancestral sequence

36

described in Kaiser et al.(260), the R35Q mutation was also introduced using PCR-based
mutagenesis into this CERV1 full-length capsid/MLV chimera.

Sequence analysis
Mutations and their dinucleotide sequence contexts were quantified using
Hypermut (http://www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html). We
generated fasta alignments using MacVector to use as input for Hypermut and the
consensus sequence for each virus family (described above) was used as a reference
sequence. The Hypermut output provided the total number nucleotide changes (each
insertion/deletion was reduced to a single nucleotide change in MacVector) as well as the
number of G to A mutations relative to the consensus sequence. Hypermut also provided
the number of G to A changes that occurred in each of the four possible dinucleotide
contexts when the nucleotide immediately 3’ to the G (or the +1 position) in the
consensus sequence is considered (i.e. GG, GA, GC and GT). To quantify the -1 position
for C to T changes, the +1 position for C to T changes, and the -1 position for G to A
changes, the reverse complement, complement, and reverse of each alignment was
generated respectively and used as Hypermut inputs. The latter two analyses allowed us
to quantify the number of C to T and G to A changes occurring in CG dinucleotides. We
repeated this analysis, after removal of G to A and C to T changes occurring in CG
dinucleotides. In some charts, the percentages of G to A or C to T changes that were in
each dinucleotide context were normalized according to the dinucleotide composition of
a given consensus sequence. P-values were calculated for these data using a chi-square
goodness of fit statistical test.
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Gene Synthesis
ClustalW alignments and majority consensus sequences of CERV2 Gag, CERV1
envelope, CERV2 envelope, and RhERV2 envelope were derived using MacVector. All
envelope sequences were collected from Ensembl using TBLASTN according to their
homology with MoMLV protein sequences first and then CERV consensus sequences
were used to blast the rhesus macaque genome to ensure the recovery of all homologues.
Sequences flanking the CA-NTDs used in the hypermutation analysis described above
were aligned with MoMLV Gag to define a CERV2 Gag open reading frame. As
described in the next chapter, a second version of CERV2 Gag was also designed that
included protease cleavage sites that matched those from MLV Gag (CERV2/MLVGag).
Overlapping oligonucleotides were designed using Genedesign from Johns Hopkins
University (http://slam.bs.jhmi.edu/gd). The target oligonucleotide length and overlap
melting temperature was set to 60 nucleotides and 56°C, respectively. EcoRI and NotI
sites were added to oligonucleotides designed to construct the 5’ and 3’ ends of the
envelope genes for cloning into the PCAGGS vector (BCCM). In the case of CERV2
Gag, the 5’ end was also designed for EcoRI recognition and at the 3’ end, 20 nucleotides
were designed to overlap with the 5’ end of MLV Pol (forward primer: 5’GagGagGAATTCATGGGACAGACTCTGACGAC -3’ reverse primer: 5’CTCCTGACCCTGACCTCCCTAATCGCTGTCCTCTCCCAGGGTCAGGACCGGGG
TGGGTTTCTTCC -3’). Primers used to amplify MLV Pol introduced 20-nucleotides at
the 5’ end that overlapped with the 3’ end of CERV2 Gag and a NotI restriction site was
introduced at the 3’ end (forward primer: 5’-
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CCTGGGagAGGACAGCGATTAGGGagGTCAGGGTCAGGag -3’ reverse primer: 5’TATATAGCGGCCGCTTAGGGGGCCTCGCGGGTTAACC -3’).
For envelope gene construction, two sequential polymerase chain reactions were
carried out. The first contained a mixture of the overlapping oligonucleotides prepared
by combining 1!L of each 100!M stock solution and then diluting ten-fold. A 50!L
PCR reaction contained 3!L of the diluted oligonucleotide mixture and gene synthesis
was carried out for 20 cycles using Phinzymes Phusion (1 min. 98°C, 1 min. 50°C, and 2
min. 72°C). The second PCR contained 2!L of crude product from the first in a 50!L
reaction with 200nM external primers. Amplification proceeded for 25 cycles (1 min.
98°C, 1 min. 55°C, and 2 min. 72°C) and the resulting product was gel-purified using the
Qiagen gel extraction kit and cloned into PCAGGS with EcoRI and NotI. Sub-cloning
between individual clones was necessary to eliminate errors in CERV1 envelope using
SpeI and RhERV2 envelope using DraI.
To construct the CERV2 Gag consensus fused to MLV Pol, first, the Gag was
synthesized much the same way as was described above for envelope genes except, due
to lower yields, there were a few protocol changes. The PCR buffer used in a 20-cyle
assembly PCR was supplemented with 3mM MgCl2 and then 3!L of this PCR was
subjected to 15 cycles of amplification using external primers. A 1.8kb product was gelpurified for use in a third PCR that ran for 20 cycles. The resulting product was gelpurified and used in an overlapping PCR with MLV Pol. The two templates were used at
equal ratio in 3% DMSO for a Phusion catalyzed, twenty-cycle reaction (1 min. 98°C, 1
min. 70°C, and 1.5 min. 72°C). After a final Qiagen gel-purification, the CERV2GagMLVPol PCR product was cloned into PCAGGS using EcoRI and NotI. To eliminate
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errors, sub-cloning was completed using KasI and NheI for CERV2 Gag and XhoI for
CERV2/MLV Gag.

APOBEC restriction assays
Human and rhesus macaque APOBEC3G with an N-terminal Myc tag was
expressed from previously described pCR3.1 constructs (156). For comparative purposes,
chimpanzee APOBEC3G was amplified from a pcDNA3.1 construct provided by
Nathaniel Landau (261) and used to replace human APOBEC3G in pCR3.1-Myc using
EcoRI and NotI. All other human APOBECs were expressed with C-terminal HA tags
from previously described pCMV4 constructs (160). Virions were produced in the
presence or absence of APOBEC proteins by cotransfection of 293T cells on 24-well
plates with 300ng of the indicated GagPol, 300ng CNCG (or CSGW with HIV GagPol),
100ng VSV envelope, and variable amounts of APOBEC as indicated. Empty pCR3.1
was used to normalize the total amount of DNA in each sample. The resulting virions
were used to infect MDTF cells overnight with 5µg/mL polybrene and, as before,
infection was evaluated according to GFP expression using the Guava Easycyte. Lysates
from virus-producing cells were ran onto 4-12% NuPAGE Bis-Tris gels (Invitrogen) and
protein was transferred to nitrocellulose membranes followed by probing with an
antibody against MLV capsid (262).

40

HIV evolution in vitro
The infectious titer of both initial viral stocks and supernatent from infected T-cell
lines was measured using the same general protocol. 104 MT2 or CEMSS cells were
seeded in 100µL in each well on a 96-well plate. Five, five-fold serial dilutions were
prepared and 50µL of each were added to cells. Following an overnight infection, further
rounds of replication were prevented using 100µg/mL dextran sulfate, a cell-entry
inhibitor (263). At two days post-infection (dpi), cells were fixed in 2%
paraformaldehyde and GFP-positive cells were quantified by FACs.
Prior to selection, HIV-1 Vif+ or #Vif (described above) were grown in MT2 or
CEMSS cells. In 25cm2 tissue culture flasks, 5x105 cells were infected with 500IU in
6mL of total volume and left overnight before a two-fold dilution with fresh media. At 4
dpi (days post infection) 10mL fresh media was added and at 6 dpi cells were transferred
to 75cm2 flasks with 40mL fresh media. Cells were split 1:3 every three days. To
maintain the MT2/Vif+ culture during virus-induced cell death, uninfected MT2 cells
were added at follows: 5x105 cells at 4 dpi, 106 cells at 6 dpi and 8 dpi, 3x106 cells at 10
dpi, and 4x106 cells at 13 dpi. In the case of both CEMSS infected cultures, 106 CEMSS
cells were added at 8 dpi and 10 dpi and then an additional 4x106 cells at 12 dpi. 100µL
aliquots were fixed periodically in 2% paraformaldehyde and stored at 4°C. Fifteen days
after infection, 50mL of each culture were spun on a tabletop centrifuge at 3000rpm for
15 minutes. The resulting supernatent was filtered through 0.22µm filters and 1.25mL
aliquots were frozen at -80°C for further analysis. Cells were washed in PBS and their
genomic DNA was extracted for PCR using the Qiagen DNeasy kit.
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To amplify sequences packaged into virions, viral RNA was extracted from
pelleted virus. In Beckman 14x89mm polyallomer centrifuge tubes, 6mL of filtered T
cell supernatent was gently layered on top of 4mL of PBS with 20% sucrose. Samples
were spun at 27000rpm in a Beckman ultracentrifuge for two hours at 4°C. The
supernatent was aspirated to ~250µL and this remaining volume was shook from the
tubes before allowing them to drain upside down for several minutes. The walls of the
tubes were dried with kimwipes. Virions were resuspended in 100µL PBS by first
incubating on ice for 90 minutes and then pipetting up and down 50 times. RNA was
extracted using the Qiagen viral RNA mini kit and cDNA was prepared using the
Invitrogen Superscript III kit and oligo-dT primers. Both this cDNA and the genomic
DNA from infected CEMSS and MT2 cells were used as PCR template to amplify the
polymerase domain of HIV-1 reverse transcriptase (forward primer: 5’CACTTTAAATTTTCCMATTAGTCCTATT -3’ reverse primer: 5’TGGCAGCACTATAGGCTGTACTG -3’). The resulting products were gel purified and
cloned using the Invitrogen TOPO zero-blunt cloning kit. Plasmid clones were
sequenced using the Genewiz SP6 primer.
AZT, nevirapine, nelfinavir, and 3TC (provided by the NIH reagent program)
were all dissolved in DMSO to 100mM. Drugs were titrated in T cell lines by first
infecting four sets of 106 CEMSS or MT2 cells with HIV-1 Vif+ at MOI 0.001 in 5mL
(eight infections total). After an overnight incubation, cells were split into 12 wells on
24-well plates in media with or without varying concentrations of each drug in 1mL per
well. Cells were collected at various time points by fixing 100µL in 2% PFA for later
quantitation of GFP+ cells. Cells were split 1:5 every four days with each drug
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concentration maintained. Selection using patient plasma was done in the same fashion
as the drug titrations, in the 24-well format to conserve plasma. The patient blood sample
was collected in heparin-coated tubes. After inactivation at 57°C for 30 minutes, 30µL
aliquots of blood plasma were prepared to avoid any additional freeze-thaw cycles after
storage at -80°C.
Selections in MT2 cells using AZT and/or nevirapine were done by infecting
4x106 cells at 0.001 MOI in 25cm2 tissue culture flasks with supernatants (Vif+ or #Vif)
collected at 15 dpi from MT2 cells (described above). One day after infection, cells were
split into plain media or media containing 4µM AZT, 4µM nevirapine, or a combination
of 4µM AZT and 500nM nevirapine. Cultures were split 1:5 every four days and enough
fresh drug was added to maintain a constant drug concentration with the conservative
assumption that no active drug still remained in the culture. This was done to prevent a
gradual decrease in drug concentration as degradation occurred over long periods of time.
The MT2 culture infected with Vif+ and lacking drug was maintained by the addition of
cells every three to four days (or when significant cell death was apparent). Selection
using nevirapine in CEMSS was carried out in the same fashion except with a different
initial procedure. 2x106 CEMSS cells were infected at 0.002 MOI with supernatent
collected from MT2 or CEMSS cells infected 15 days prior with Vif+ or #Vif virus. At 3
dpi, 500nM nevirapine was added to half of the infected cells.

Receptor Screen
Twenty pools of 2x105 PGSA were transduced with the HeLa cDNA library (MOI
0.5) one day after plating in 6-well dishes. Cells were expanded to 15cm dishes the
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following day and selection with 200!g/mL zeocin began that evening. Each pool was
grown under selection for six days before plating in duplicate at 105/well on a 12-well
dish. The following day, cells were infected with CERV2 enveloped virions carrying a
CMV-Neo MLV vector (MOI 3.5). One uninfected and two minus-library controls were
carried forward in parallel. Each of the 43 groups of cells were expanded to 100mm
dishes one day after infection and one day prior to the addition of 1mg/mL G418.
Following ten days of G418 selection, colonies were pooled as 20 separate groups
corresponding to the original 20-pool PGSA cell expression library. 2.5x104 cells from
each of these colony pools were infected independently with CERV2 enveloped LHCX
virions in a 48-well plate (MOI 1.0). One day after infection, cells were transferred to 6well plates and then placed under selection with 100!g/mL hygromycin on the following
day. Genomic DNA was extracted from surviving cells using the Qiagen DNeasy kit and
used as PCR template with primers designed to anneal to DNA flanking the
LMN8iresZeo cloning site (forward primer: 5’- ATACACGCCGCCCACGTGAAGG -3’
reverse primer 5’- GCTTCCTTCACGACATTCAACAGACC -3’). The resulting
products were cloned using the Invitrogen TOPO zero-blunt cloning kit and four colonies
from each were sequenced using the SP6 primer.

Virion Binding
GFP-labeled virus particles were generated by overnight PEI co-transfection of
293T cells with 5!g MLV Gag-GFP expression plasmid (a gift from David PerezCaballero) and 5!g PCAGGS-CERV2envelope or 5!g PCAGGS on 100mm dishes. The
virion-containing supernatant was harvested two days post-transfection and purified
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through a 0.22!m filter. CHO cells or a single-cell clone of CHO-humanCTR1 were
seeded two days prior to binding onto a poly-lysine coated 15mm coverslip within a
35mm dish at 105 cells/dish. Cells to be used for virion binding in the presence of copper
were incubated with 20!M CuCl2 for two hours at 37°C. All cells were then incubated in
media containing 20mM HEPES pH 7.2 at 4°C for 20 minutes. 980!L virion-containing
supernatent was supplemented with 20mM HEPES pH 7.2, 5mg/mL polybrene, and
20!M CuCl2 or water in 1mL of total volume, applied to aspirated cells at 4°C, and
incubated at 4°C for one hour. The cells were washed three times with filtered PBS at
4°C before fixation for 20 minutes at room temperature with 4% paraformaldehyde. The
cells were then washed twice with PBS.

RNA-interference
A Dharmacon siGENOME smart pool was used to knockdown CTR-1 and
included RNA designed to target the following sequences within the CTR1 open reading
frame: 5’-AGGCAGUGGUAGUGGAUAU-3’, 5’-CUGCGUAAGUCACAAGUCA-3’,
5’-GGAACCAUCCUUAUGGagA-3’, and 5’-CAUAUGGGGAUGagCUAUA-3’. Cells
were seeded on 24-well dishes 24 hours prior to transfection at 105cells/well. Media was
replaced with Gibco Optimem 2 hours prior to transfections and then again 20 minutes
before transfections. Invitrogen Lipofectamine 2000 was used to co-transfect cells with
10pmol of pooled siRNA and 300ng of DsRED expression plasmid (transfection
efficiency marker) according to the manufacturer’s instructions. Following 6 hours of
transfection, cells were supplemented with 1mL DMEM 10% FBS without antibiotics.
The transfection was repeated the following day. One hour after the addition of fresh
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media to the second transfection, cells were trypsinized and seeded on a 96-well plate at
104cells/well for infection the following day. To validate RNAi activity, transfections
were repeated as described above except 500ng of PCR3.1-HA-CTR1 was included in
the first of two siRNA transfections. Cells were collected for western blot in SDS-PAGE
loading buffer two days after the first transfection.
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Chapter III. Were TRIM5 and APOBEC3 proteins capable of
restricting CERV1 and CERV2?

CERV1 and CERV2 capsid N-terminal domains
To investigate the host range limitation and extinction of chimpanzee endogenous
retrovirus groups one and two (CERV1 and CERV2), it was first determined whether
TRIM5 restriction factors could have been capable of targeting them during their
exogenous replication. Toward this purpose, we studied CERV1 and CERV2 capsid Nterminal domain (CA-NTD) sequences found in the chimpanzee genome as well as their
homologues in the rhesus macaque (RhERV1 and RhERV2). The CA-NTD appears to
contain all determinants of TRIM5" recognition; this is intuitive given that its highly
conserved structure comprises the surface of the retroviral core, which is exposed to
TRIM5" following entry into a target cell (108-111, 113, 114). Therefore, CERV1 and
CERV2 CA-NTDs in the context of functional chimeric virions are sufficient to test
whether TRIM5" was able to restrict these viruses. An ability to target CERV1 and
CERV2 capsids would indicate that TRIM5" proteins could have been capable of
restricting transmissions during their exogenous replication. The use of a minimal
portion of the endogenous retroviruses also increased the likelihood of including intact
and functional open reading frames from proviruses that contained frequent mutations.
Endogenous murine leukemia viruses (enMLV) were also included for comparison.
All sequences were compiled by BLAST searches of the Pan Troglodytes,
Macaca mulatta and Mus musculus genome sequence databases and were then used to

47

Figure 6. Phylogenetic tree of ancient primate gammaretroviral capsid NTDs. A sequence
alignment, and phylogeny of all capsid NTDs from CERV1, CERV2, RhERV1a, RhERV1b,
RhERV2, and enMLV and various prototype gammaretroviruses was generated using ClustalX
software. The tree diagram was generated and edited using FigTree software.

derive group-specific capsid consensus sequences. A phylogeny of all retrieved
endogenous CA-NTDs, as well as those from several other gammaretroviruses, was
constructed (Figure 6). A monophyletic group of 85 unique CERV1 CA-NTD sequences
was found in the chimpanzee genome, which were closely related to 48 sequences found
in the rhesus macaque (RhERV1a). A second, more distant group of 28 CERV1
homologues was also compiled from the rhesus macaque genome database and termed
RhERV1b. CERV2, which is more closely related to moloney MLV than CERV1,
includes ten CA-NTD sequences in the chimpanzee genome and 44 orthologues in the
rhesus macaque (RhERV2). CERV2 and RhERV2, based on their capsid sequences,
appear to be closely related to the baboon endogenous retrovirus (BaEV). The mouse
genome database contained 41 unique MLV CA-NTD sequences that are from three
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groups of endogenous retroviruses (enMLV) previously described as xenotropic,
polytropic, and modified polytropic MLV (72).

MLV Chimeric Viruses containing primate and mouse endogenous
gammaretroviral CA-NTDs are generally resistant to TRIM5! proteins
To test ancient retroviruses for sensitivity to TRIM5 proteins, functional virions
were constructed that contained CA-NTDs from endogenous retroviruses. Libraries of
chimeric MLV GagPol were constructed by amplifying CA-NTDs from chimpanzee,
rhesus macaque, and mouse genomic DNA and cloning the resulting products in place of
the native MLV CA-NTD. It is possible that diversity in such a library is not only the
result of natural sequence variations, but could also contain contributions from
recombination of highly similar sequences or DNA polymerase errors during PCR.
Therefore, in order to be conservative, only sequences that perfectly matched those found
in the sequence database were included in the experiments below.
Mus dunni tail fibroblasts (MDTF), that were either unmanipulated or made to
stably express TRIM5" proteins, were infected with MLV virions carrying recombinant
GagPol proteins. MDTF were chosen due to the lack of a TRIM5" gene in mice. The
CA-NTD of the TRIM5" resistant moloney MLV GagPol was replaced with that from Nor B-tropic MLV, or with endogenous retroviral CA-NTDs. The resulting recombinant
MLV particles also carried a minimal MLV genome encoding a GFP reporter and were
enveloped with VSV-G to allow efficient infection of MDTF. This system allowed for
only a single cycle of replication and infections were quantified based on the percentage
of MDTF expressing GFP.
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As expected, MLV particles carrying the CA-NTD from an N-tropic, but not Btropic, MLV were restricted by the human, chimpanzee, African green monkey TRIM5"
proteins and also, to a lesser degree, by the rhesus macaque TRIM5". These restricted
infections served as controls to demonstrate the functionality of the stably expressed
TRIM5" proteins, as well as to confirm that swapping the CA-NTD was sufficient to
confer TRIM5" sensitivity. Virions containing CA-NTDs that matched the majority
consensus sequence of CERV1 and CERV2 were both infectious (~104 IU/mL) and were
not restricted to any degree by human, chimpanzee, rhesus macaque, or African green
monkey TRIM5", or by owl monkey TRIM-cyclophilinA (Figure 7A). It should be
noted that these results are in sharp contrast to those reported by Kaiser et al., in which
both an ancestral CERV1 full-length capsid (both NTD and CTD) and p12 were included
in an MLV chimera and this virus was restricted by human and chimpanzee TRIM5".
Aside from including a larger portion of CERV1, the ancestral CERV1 capsid used by
Kaiser et al. differed by one amino acid from the CERV1 consensus CA-NTD used here
(glutamine instead of arginine at position 35). To address this discrepancy, recombinant
MLV GagPol genes were constructed that contained full-length CERV1 capsids with
either the ancestral or majority consensus sequences. Importantly, inclusion of the entire
CERV1 CA did not confer any TRIM5" sensitivity to the chimeric MLV virions (Figure
7B). Furthermore, TRIM5" resistance was observed regardless of whether the consensus
or the ancestral CERV1 capsid was used (glutamine or arginine at residue 35,
respectively).
MLV recombinants containing consensus CA-NTDs as well as several functional
variants from CERV1, CERV2, RhERV1a, RhERV1b, RhERV2 and enMLV were tested
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for sensitivity to TRIM5 proteins as well as to the murine capsid-dependent restriction
factors, Fv1N and Fv1B (Figure 7C, D). As was described above for particles containing
consensus CERV1 and CERV2 CA-NTDs, nearly all chimeric MLV pseudotypes tested
displayed resistance to restriction by a variety of primate TRIM5" proteins and owl
monkey TRIM-Cyp. In addition, all primate endogenous CA-NTDs were also insensitive
to Fv1. With the exception of one variant, the enMLV CA-NTDs conferred a B-tropism
to recombinant particles in that they were sensitive to Fv1N and Fv1NB, but insensitive to
Fv1B and TRIM5 proteins.
Only one ancient CA-NTD displayed a TRIM5-sensitive phenotype. This
exception to the general TRIM5 resistance observed in all other recombinants was an
MLV/RhERV2 recombinant (#58) that was restricted by chimpanzee TRIM5" and
marginally by human TRIM5", but was insensitive to rhesus macaque TRIM5" (Figure
7E). This particular RhERV2 CA-NTD contained four amino acid differences relative to
the RhERV2 consensus; one of which, E91K, was not carried by any of the other
RhERV2 CA-NTDs tested. On the MLV CA-NTD structure, residue 91 is predicted to lie
on the exterior face of the mature core, making it a reasonable putative determinant of
TRIM5" sensitivity (Figure 7F). Indeed, when the E91K mutation was introduced into
the RhERV2 consensus CA-NTD, the resulting MLV recombinant displayed the same
TRIM5" sensitivity as variant #58 (Figure 7E). Therefore, residue 91 is a novel
determinant of TRIM5" restriction. Interestingly, the E91K mutation is shared by ~20%
of all RhERV2 capsids reported in the genome database, but it is not found in CERV2.
This, coupled with the observation that the E91K mutant displayed sensitivity to
chimpanzee but not rhesus macaque TRIM5", suggests that a selective pressure may
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Figure 7. Resistance of chimeric MLVs containing primate gammaretroviral CA-NTDs to
primate TRIM5 proteins A) MLV chimeric viruses encoding CA-NTD consensus
sequence from CERV1 and CERV2 were used to infect MDTF cells expressing human,
chimpanzee, rhesus or African green monkey TRIM5" or Owl Monkey TRIMCyp
proteins. GFP positive cells were quantified by FACS (Guava EasyCyte) 48h after
infection. N-MLV and B-MLV were used as controls. B) MLV chimeric viruses
containing an entire ancestral CERV1 capsid sequence (CERV-1(anc)), an entire
consensus CERV1 capsid sequence (CERV1(con)) or a consensus CERV1 CA-NTD
fused to an MLV CTD (as in A) were used to infect MDTF cells expressing the indicated
TRIM5 proteins. N-MLV and B-MLV were used as controls and infection was evaluated
as in A). C) MLV-chimeric viruses encoding natural variant CA-NTDs from CERV1,
RhERV1a, or RhERV1b were used to infect MDTF cells expressing various TRIM5 and
Fv1 proteins. D) MLV-chimeric viruses encoding natural variant CA-NTDs from
CERV2, RhERV2 and enMLV were tested as in A). E) MLV chimeric viruses encoding a
consensus RhERV2 CA-NTD, a natural variant CA-NTD that includes the E91K
mutation (RhERV2 58), or an E91K point mutant were tested as in A). F) Representation
of the MLV CA-NTD with the positional equivalent of the RhERV2 E91 residue colored
red. The left picture shows a side view of the CA-NTD monomer (outer surface of the
capsid at the top) while the right picture shows a view of a single CA-NTD hexamer,
viewed from the outside of what would be a complete core.
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have existed in the chimpanzee lineage that was able to prevent the transmission and/or
emergence of this particular mutation. In general, though, the TRIM5" resistance
displayed by all the other CA-NTD variants tested suggests that it is unlikely that
TRIM5" was able to impose complete transmission barriers against the CERV1 and
CERV2 families. In particular, the human TRIM5" displayed only marginal activity
against RhERV2 capsids carrying the E91K mutation and was completely inactive
against all others, which argues against a general protective role for human TRIM5"
during potential transmissions of CERV1 and CERV2 to the human lineage.

Evidence of endogenous gammaretrovirus restriction by APOBEC3 family
members
Several APOBEC3 cytidine deaminases are capable of restricting retrovirus
replication and a hallmark of their activity is the production of G to A hypermutation
within specific sequence contexts. A Bias in CERV1 and CERV2 sequence variability
toward these APOBEC3-associated mutations would suggest that these viruses were
subject to just such an activity during their exogenous replication. This would suggest a
potential role for APOBEC3 restriction factors in the extinction and/or inter-species
transmissions of exogenous CERV1 and CERV2.

In order to search for signs of past

APOBEC3 activity, majority consensus sequences were derived for CA-NTDs from
CERV1, RhERV1a, RhERV1b, CERV2, RhERV2, and enMLV. Within each of these
groups, any deviation from the consensus sequences was documented. A striking degree
of conservation was observed in all groups of CA-NTDs with a typical divergence from a
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given majority consensus sequence of <3%. In several groups, though, there existed a
high relative abundance of G to A and C to T mutations (Figure 8A). Furthermore, the
relative levels of G to A and C to T mutations varied both between homologues and
within a given host species. In RhERV2 sequences, half of all nucleotide differences
found in the CA-NTDs were G to A mutations. On the other hand, G to A mutations in
CERV1, CERV2, RhERV1a, and RhERV1b CA-NTDs occurred at frequencies that were
similar to C to T mutations and both were present at a lower level than all other mutations
pooled together. Also in contrast to the mutations in RhERV2 CA-NTDs were those
found in enMLV CA-NTDs, in which the majority were from neither G to A nor C to T
substitutions.
The most common nucleotide mutations found in mammalian genomes are
generally G to A and C to T transitions, which are typically caused by spontaneous
deamination (described below). APOBEC3-induced deamination of viral reverse
transcripts can be distinguished from spontaneous deamination of the host genome by the
existence of certain biases in the dinucleotide context of the mutations. Namely,
APOBEC3G specifically deaminates CC dinucleotides on the cDNA minus strand to CU,
whereas primate APOBEC3F, 3B, and 3H and murine APOBEC3 all mutate TC to TU
(153-155, 160, 170, 171). These changes, made during reverse transcription, manifest in
the positive strand sequence as GG to AG or GA to AA mutations. Additionally, rare
deamination of cytidine residues on HIV-1 RNA by APOBEC1 has been reported (194).
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Figure 8. Analysis of ancient ERV CA-NTDs. A) The mean number of G to A, C to T,
and all other changes (pooled) per CA NTD sequence, relative to each consensus
sequence is shown. B) The numbers of G to A mutations for each individual CA-NTD
recovered from sequence databases is plotted as a bar graph (one bar for each provirus)
and color-coded according to dinucleotide context (i.e. the nucleotide in the +1 position
relative to the G to A change; red = GG to AG, cyan = GA to AA, green = GC to AC,
magenta = GT to AT). The CA NTD sequences are arranged from left to right in order of
increasing numbers of total G to A changes. C) The mean number of G to A changes per
CA-NTD sequence, relative to the consensus, is plotted for pooled data for each virus
species and color coded according to dinucleotide context as in B. C) The percentage of
G to A changes in each dinucleotide context relative to consensus sequence is plotted,
and normalized according to the dinucleotide composition of the species-specific
consensus sequences. The p-values for deviation from a random distribution were
calculated using the chi-squared test.
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In order to ask whether the excessive G to A and C to T changes found in the
endogenous gammaretroviruses were caused by spontaneous deamination of proviruses
in the host genome or by the catalytic action of antiviral deaminases, the dinucleotide
context of these mutations was quantified to detect any biases that may have existed.
Because the number of mutations observed in each individual CA-NTD was rather small,
we inspected both the pooled CA-NTD sequence data from each viral species (Figure 8C)
as well as the individual CA-NTD sequences (Figure 8B). There was significant variation
in the burden of G to A mutations among individual CA-NTDs: while some completely
lacked G to A mutations, others contained up to 12 G to A mutations in the ~400
nucleotide CA-NTD encoding sequence (Figure 8B). Moreover, striking and variable
biases in the patterns of G to A mutations were observed. For example, in CERV1 CANTDs, G to A changes occurred primarily in the context of GG dinucleotides (Figure 8B,
C). This bias was statistically significant, and was maintained when corrected for the
frequency with which each GN dinucleotide occurred in the consensus sequence (Figure
8D). In CERV2 CA-NTDs, the occurrence of G to A changes was biased toward both GG
and GC dinucleotides; however, in this case the overall numbers of G to A changes were
small (Figure 8B) because only 10 CERV2 proviruses are present in chimpanzee DNA.
Interestingly, compared to each of their chimpanzee counterparts, the rhesus macaque
endogenous gammaretroviruses RhERV1a and RhERV2 exhibited a different mutational
bias: G to A mutations occurred frequently at both GG and GA dinucleotides, and these
biases were also highly statistically significant (Figure 8B, C). In contrast, RhERV1b CA
NTDs were quite different in that they had relatively few G to A mutations and their
occurrence was unbiased with respect to dinucleotide context (Figure 8B).
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Confirmation of mutational biases in endogenous gammaretroviruses
The sequence analyses above suggested that some endogenous proviruses may
well have encountered antiviral cytidine deaminases. Therefore, to confirm and extend
these observations, we asked if similar patterns of mutation could be observed in another
region of the endogenous proviruses, in particular envelope (Env) sequences (Figure 9).
Because there are large numbers of CERV-1 proviruses and the chimpanzee genome
database contained abundant unresolved regions, we retrieved only envelope sequences
that were linked to CA-NTDs that had either $1 G to A mutations or %4 G to A mutations
(10 of each). Overall, there was a good correlation between the CA-NTD and Env
sequences in terms of the burden of the G to A mutations and the dinucleotide context in
which they occurred (Figure 10 A, B). Specifically, the occurrence of GG to AG
mutations in a given CERV1 CA-NTD strongly predicted the occurrence of the same
type of mutation in the linked Env sequence, while CA-NTD sequences that contained
one or no G to A mutations were linked to envelopes that contained relatively few G to A
mutations that largely lacked a dinucleotide bias. Indeed, there was only one exception to
this finding among the 20 CERV-1 sequences analyzed, in which a CA-NTD bearing
three GG to AG mutations was linked to an Env sequence containing a light and unbiased
burden of G to A changes (Figure 10 A, B).
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Figure 9.
Phylogenetic tree illustrating the relationship between endogenous primate
gammaretroviral Env sequences and other gammaretroviral Envs. A sequence alignment, and
phylogeny of Env sequences from CERV1, CERV2, RhERV1a, RhERV1b, RhERV2, and
enMLV and various prototype gammaretroviruses was generated using ClustalX software. The
tree diagram was generated and edited using FigTree software.

Because there are only ten CERV2 proviruses in the chimpanzee genome (and
only four of them are complete, with others ranging in size from 2.6 to 7.7 kb) we took a
different approach to confirm or refute the notion that they contained excessive or biased
G to A mutations. Specifically, we analyzed all of the available sequence for all ten
proviruses. In part because the CERV2 proviruses were intrinsically divergent, and
differed in length, the absolute numbers of G to A changes as compared to the consensus
sequence was quite variable among them (Figure 10C). However, when the character of
the G to A mutations was examined, five of the 10 proviruses exhibited a clear,
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statistically significant, excess of GG to AG mutations, as compared to overall G to A
changes (Fig 10C). Thus, the patterns of nucleotide substitutions strongly suggested that
both groups of endogenous gammaretroviruses that integrated into the chimpanzee
genome in the past few million years frequently encountered the only mutagen known to
preferentially induce GG to AG mutations, namely APOBEC3G, prior to or during
endogenization.
The coverage of the rhesus macaque reference genome database was less
complete compared to that of the chimpanzee, so only 23, 10 and 22 envelope sequences
that were unambiguously linked to CA-NTDs could be retrieved for RhERV1a,
RhERV1b and RhERV2 respectively. Moreover, in the case of RhERV2, the CA-NTD
linked env genes were distributed between two distinguishable subgroups and, therefore,
a separate Env consensus sequence was deduced for each group. For both RhERV1b and
RhERV2 the analysis of env sequences corroborated the results obtained using CA-NTDs
(Fig 10, B). Specifically, the numbers of G to A changes in RhERV1b Env, like CANTD sequences were modest and unbiased with respect to dinucleotide context; while in
RhERV2, there was a clear excess of both GG to AG and GA to AA mutations in both
CA-NTD and Env sequences (Figure 10A, B). However, while there was concordance
with respect to overall context bias of G to A mutations present in RERV2 CA-NTD and
Env sequences, inspection of individual linked CA-NTD and Env sequences revealed that
the burden and character of G to A mutations was variable. Specifically, several Env
sequences bore a large proportion of G to A substitutions in GA dinucleotides while two
other Env sequences bore predominantly GG to AG hypermutation. Additionally, the
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Figure 10. Analysis of G to A changes in CA-NTD and Env sequences in primate
gammaretroviruses. A and B) CA-NTD sequences from the primate gammaretroviruses
were selected according to whether an unambiguously linked Env sequence could be
retrieved from the genome database. In the case of CERV1, ten sequences that essentially
lacked G to A changes and Ten sequences that had four or more G to A changes were
selected. For each virus species each sequence is plotted as a bar graph (one bar for each
provirus) and color-coded according to dinucleotide context (i.e. the nucleotide in the +1
position relative to each G to A change; red = GG to AG, cyan = GA to AA, green = GC
to AC, magenta = GT to AT). The CA NTD sequences are arranged from left to right in
order of increasing numbers of total G to A changes in CA-NTD sequences (A). The
same analysis was performed for the linked env sequences (B), which are arranged in
order according to the linked CA-NTD sequence. C) All ten CERV2 proviral sequences
were analyzed and the dinucleotide context in which G to A mutations occurred is plotted
and color-coded as in A (left) panel. Additionally, The percentage of G to A changes in
each dinucleotide context relative to consensus sequence is plotted, and normalized
according to the dinucleotide composition of the consensus sequences (right panel). The
p-values for deviation from a random distribution were calculated using the chi-squared
test. Proviruses 1, 4, 6 and 7 are complete.
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degree to which CA-NTDs and Env sequences were mutated in individual proviruses did
not always correlate; in some cases hypermutated RhERV2 Env sequences were linked to
CA-NTD sequences that bore relatively few G to A changes (Figure 10A, B). In
RhERV1a, the nature and burden of G to A changes in Env sequences was not at all
predicted by the findings in the CA-NTD sequences. Indeed, the preferential occurrence
of G to A changes in Env in the context of GG and GA dinucleotides was marginal, and
clearly less pronounced than in the CA-NTD sequences (Fig 10, A, B). These results,
and the discordant findings with respect to G to A mutation in a few RhERV2 CA-NTD
versus linked Env sequences are either explained by variable mutation frequencies across
genomes (a known characteristic of APOBE3G induced mutation) or by recombination
between hypermutated and non-hypermutated viral genomes that occurred prior to or
during deposition in the germ line. Indeed, inspection of several complete or nearly
complete RhERV2 proviruses revealed clear variation in the extent of G to A mutation in
some (but not all) proviruses across the viral genome (Figure 11). Notably, an obvious 5’
to 3’ gradient of increasing mutation intensity was present in some examples bearing
excessive G to A mutations, as has previously been reported in hypermutated HIV-1
genomes (171, 172). Also, several recombination break points were implied by abrupt
differences in the frequency of APOBEC3-induced mutation.
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Figure 11. Examples of the RhERV2 proviruses illustrating variation in type, burden, and
distribution of G to A mutations among endogenous primate gammaretroviruses. Each horizontal
line represents a complete or nearly complete ~8.5kB provirus (nucleotide position scale is given
at the bottom of the diagram), vertical marks indicate the position of G to A mutations relative to
the RhERV2 consensus sequence and are color coded according to dinucleotide context (i.e. the
nucleotide in the +1 position relative to each G to A change; red = GG to AG, cyan = GA to AA,
green = GC to AC, magenta = GT to AT). Yellow marks indicated non-G to A mutations,
including in/dels.

Biased patterns of G to A mutation in primate ERVs are not explained by
spontaneous cytidine deamination
The chimpanzee and rhesus gammaretroviral CA-NTD and Env sequences also
contained a striking excess of plus strand C to T changes relative to their respective
consensus sequences (Figure 8A). Potentially, the high rate of C to T mutations in CANTD sequences could be the result of cytidine deamination after integration of the
provirus into the germ line. Correspondingly, excessive plus strand G to A changes could
be a reflection of cytidine deamination events on the minus strand within the host
genome. In contrast to APOBEC3-mediated deamination events, which occur
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specifically on the anti-sense DNA strand and are profoundly influenced by the identity
of the nucleotide in the -1 position relative to the deaminated cytidine, mutations that
arise as a result of cytidine deamination in the host genome are influenced by the
nucleotide in the +1 position and lack any strand specificity. Specifically, the most
common cytidine deamination-induced mutation found in mammalian genomes occurs in
the context of CG dinucleotides (i.e. G in the +1 position). This results in CG to TG or
CG to CA sense mutations depending on whether CG dinucleotides on the plus or minus
strand are deaminated, respectively (264, 265). This phenomenon is explained by a
transcriptional control mechanism that operates by cytidine methylation of CG islands.
When genomic 5-methyldeoxycytosine is deaminated, deoxythymidine is formed.
Therefore, if a CG to TG mutation (or its anti-sense counterpart, CG to CA) is found in
an endogenous retrovirus it is likely the result of deamination of proviral nucleotides
during long-term residence in the host genome as opposed to deamination by restriction
factors during exogenous replication. Interestingly, it is possible that deamination of CG
dinucleotides in the cellular genome is catalyzed by the APOBEC family member,
activation-induced cytidine deaminase (AID). This is suggested by the observation that
AID expression is required for proper demethylation in pluripotent stem cells (266, 267).
It was proposed that during reprogramming of gene expression, silenced DNA can be
demethylated through the deamination of methyl-cytidine followed by T:G base excision
repair by glycosylases. If this mechanism resulted in mutations of endogenous
retroviruses, though, it would be due to their presence in the cellular genome rather than
the result of a specific antiviral activity.
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To account for the potential “noise” introduced by deamination in the cellular
genome, we counted and categorized all G to A and C to T changes for both CA-NTD
and Env sequences before and after exclusion of CG dinucleotides (Figure 12). Notably,
in an analysis of plus strand C to T mutations there were no evident biases in the -1
position after the exclusion of substitutions that occurred in CG dinucleotides (Figure
12C, D). This confirms that the APOBEC3 activities identified had minus-strand
specificity. Moreover, exclusion of C to T mutations that occurred in the context of CG
dinucleotides on the minus strand, reduced the overall number of plus strand G to A
mutations but did not affect conclusions with respect to their associated dinucleotide
context biases (Figure 12A, B).
Notably, the relative extent of G to A as compared to C to T mutations varied
among individual proviruses of a given virus group as well as between virus groups. This
was most evident in the analysis of Env sequences (or complete proviral sequences in the
case of CERV2), because the longer length of sequence analyzed permitted a more robust
estimate of G to A and C to T mutation frequencies (Figures 13, 14). For many of the
individual CERV1, CERV2, and RhERV2 proviruses, the frequency of G to A mutations
greatly exceeded the frequency of C to T mutations (Figure 13A, C, Figure 14), and in
proviruses where this was the case, the excessive G to A mutation was invariably in the
context of GG or GA dinucleotides, and remained evident when CG dinucleotides were
purged from the analysis (Figure 13B, D and Figure 14). Conversely, RhERV1a and
RhERV1b Env sequences exhibited broadly similar levels of comparatively unbiased G
to A and C to T mutation (Figure 13) suggesting that the frequency of APOBEC3induced mutation was low compared to that from other sources. A comparison with
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Figure 12. Comparative analysis of the context in which G to A versus C to T changes
occur in primate gammaretroviral CA-NTDs. (A) Each sequence is plotted as a bar graph
(one bar for each provirus) and color-coded according to dinucleotide context (i.e. the
nucleotide in the +1 position relative to each G to A change; red = GG to AG, Cyan =
GA to AA, Green = GC to AC, magenta = GT to AT) the CA NTD sequences are
arranged from left to right in order of increasing numbers of total G to A changes in CANTD sequences (panel A contains the same data as Figure 10A) (B) Same analysis as in
A, except mutations were enumerated after removal of minus strand CG to TG (plus
strand CG to CA) mutations. (C) Analysis of plus strand C to T mutations, in the same
CA-NTD sequences, in the same order, (left to right) as in A and B. C to T changes are
color-coded according to the nucleotide in the -1 position relative to each C to T change;
red = CC to CT, Cyan = TC to TT, Green = GC to GT, magenta = AC to AT) (D) Same
analysis as in C, except mutations were enumerated after removal of plus strand CG to
TG mutations.
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endogenous MLVs revealed a similar situation to that in primate gammaretroviruses, and
as was previously reported, two out of the three groups of endogenous MLVs (Pmv,
Mpv, but not Xmv) exhibited higher levels of G to A than C to T mutations, and this
excess in G to A mutations was associated with similar context biases (268). Overall,
clear dinucleotide context biases were observed in each situation where G to A mutations
clearly outnumbered C to T mutations.
Thus, the excessive and context-biased G to A mutations that are present in some
of the groups of primate endogenous gammaretroviruses cannot be explained by
spontaneous cytidine deamination. Rather, the analysis of both CA-NTD sequences, and
linked envelope sequences, provides robust support for the hypothesis that APOBEC3G
in chimpanzees, and a combination of APOBEC3G and other APOBEC3 proteins in
rhesus macaques, extensively mutated ancient gammaretroviral genomes prior to and/or
during their endogenization. If endogenization involved multiple rounds of replication in
reproductive organs, then the high expression levels of APOBEC3 proteins in the ovaries
and testes suggest that they may have been able to act on viruses during endogenization
(269).
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Figure 13. Comparative analysis of the burden of, and the context in which, G to A
versus C to T changes occur in endogenous primate and murine gammaretroviral Env
sequences. (A) Each sequence is plotted as a bar graph (one bar for each provirus) and
color-coded according to dinucleotide context as before. The primate Env sequences are
derived from the same proviruses as the CA-NTD sequences shown in Figure 12, and
arranged from left to right in the same order (panel A contains the same data as Figure
10B) (B) Same analysis as in A, except mutations were enumerated after removal of
minus strand CG to TG (plus strand CG to CA) mutations. (C) Analysis of plus strand C
to T mutations, in the same Env sequences, in the same order, (left to right) as in A and
B. C to T changes are color-coded according to the nucleotide in the -1 position relative
to each C to T change as before. (D) Same analysis as in C, except mutations were
enumerated after removal of plus-strand CG to TG mutations.
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Figure 14. Comparative analysis of the burden of, and the context in which, G to A versus C to T
changes occured in CERV2 proviruses. (A) Each sequence is plotted as a bar graph (one bar for
each provirus) and color-coded according to the dinucleotide context in which G to A mutations
occur, as described above. The proviral sequences correspond to the CA-NTD sequences shown
in Figure 12, and arranged from left to right in the same order. The left panel shows analysis
without removal of minus strand CG dinucleotides, while the right panel shows analysis after
their removal. (B) Analysis of plus strand C to T mutations, in the same CERV2 proviral
sequences, in the same order, (left to right). C to T changes are color-coded according to the
nucleotide in the -1 position relative to each C to T change as is Figure 12. The left panel shows
analysis without removal of plus strand CG dinucleotides, while the right panel shows analysis
after their removal.
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Effects of cytidine deamination on ancient primate gammaretrovirus CA-NTD
function
Inspection of the endogenous primate gammaretroviral CA-NTD sequences
revealed that, with the exception of RhERV1b CA-NTD sequences, many harbored stop
codons (Figure 15A). Strikingly, G to A mutations generated a large fraction of the stop
codons. C to T changes resulted in stop codons somewhat less frequently than G to A
changes, but still provided a major source of these obviously inactivating mutations.
Frameshifts and other mutations were responsible for only a small proportion of protein
truncating mutations. Many of the C to T changes occurred in CG dinucleotides and are
therefore likely to be caused by spontaneous post-integration deamination events.
Notably, all of the stop codons that arose through the appearance of G to A mutations
were due to a change from Trp (TGG) to termination codons (TAG, TGA or TAA), often
reflecting the dinucleotide bias associated with the G to A changes observed in those
species. The large number of stop codons generated at Trp codons, likely by APOBEC3mediated cytidine deamination, would almost certainly functionally inactivate many of
these ancient endogenous retroviruses. Note that this analysis was confined to the CANTD sequences, and thus indicates the predominate source of termination codons, but
significantly underestimates the total number of termination codons in full-length
proviruses.
In addition to stop codons, G to A and C to T changes introduced missense
mutations in CA NTDs whose effects cannot be determined simply by inspecting
sequence data. Although it was not practical to determine the effect of each G to A and C
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to T mutation in isolation, a few (fourteen) members of the libraries of chimeric CERV1RhERV1a- or RhERV1b-MLVs bore single, naturally occurring, missense mutations that
could likely be attributed to enzymatic cytidine deamination (GG to AG changes) or
spontaneous cytidine deamination (CG to CA or CG to TG changes). Chimeric MLVs
bearing these single mutations were invariably less infectious than corresponding MLVs
encoding the intact CERV1, RhERV1a or RhERV1b consensus CA-NTD sequence
(Figure 15B). The magnitudes of the decreases in infectivity were variable, and in one
case a missense GG to AG mutation completely inactivated a CERV1-MLV chimera.
Thus, amino acid differences from the consensus, likely attributable to enzymatic or
spontaneous cytidine deamination decreased infectivity, suggesting that they were
unlikely to be positively selected to provide benefit to a replicating virus. Rather, in
addition to their propensity to induce the occurrence of termination codons, the abundant
nonsynonymous G to A and C to T changes likely contributed significantly to a
deleterious genetic load borne by these populations of endogenized viruses.
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Figure 15. Effects of cytidine deamination on CA-NTD function. A) the percentage of translation
termination codons generated by G to A, C to T, frameshift and other mutations in endogenous
primate and mouse gammaretroviral CA-NTDs. The percentage of all CA-NTD sequences with
stop codons in CERV1, CERV2, RhERV1a, RhERV1b, RhERV2, and enMLV CA-NTDs is
plotted and the colored subdivision indicate the proportions that are attributable to each type of
mutation. B) Effect of single G to A and C to T missense mutations on the infectivity of chimeric
MLVs bearing CA-NTDs from primate endogenous retroviruses. Consensus capsid NTDs from
the indicated virus species and variants bearing single naturally occurring G to A mutations (red)
or C to T mutations (cyan) were introduced into chimeric MLV GagPol and infectivity measured
as in Figure 7. Note that all three G to A mutations in CERV1 (#46, #23, #34) occurred in the
context of GG dinucleotides, while the mutations in RhERV1a and RhERV2 were all in the
context of CG dinucleotides on the plus strand (blue) or minus strand (red).

CERV2 restriction by APOBEC3 proteins in vitro
It is clear from the analyses presented above that APOBEC3G was capable of
heavily mutating CERV2, but this alone does not necessarily indicate that APOBEC3G
was able to broadly restrict its replication. Indeed, APOBEC3G is able to induce
mutations in HERV-K without restricting a HERV-K consensus during a single cycle of
replication (13, 270). Also, in spite of the ability of HIV-1 to avoid restriction by human
APOBEC3 proteins through the action of Vif, hypermutated proviruses are abundant in

76

infected patients (192, 193, 197, 271). Furthermore, HIV-1 can accumulate APOBEC3associated mutations in cells that allow equal replication of Vif-deficient and Vifproficient viruses (Chapter IV). These results point out that APOBEC3-induced mutation
is observable even when viruses are not susceptible to its restrictive effects. Thus, it
becomes necessary to confirm, in vitro, that APOBEC3G is capable of restricting CERV2
infection.
It has been posited that the incorporation of APOBEC3G into HIV particles
occurs through its interaction with virion-packaged RNA and nucleocapsid (162-168).
Even in the absence of viral RNA, though, APOBEC3G was shown to both incorporate
into virions and interact with Gag in an RNA- and nucleocapsid-dependent manner (162,
164, 165, 168). This suggested that APOBEC3 packaging depends, not on specific
sequences in the viral genomic RNA, but on nucleocapsid and, in particular, its ability to
bind RNA. Further importance of nucleocapsid in APOBEC packaging has been shown
for human T cell leukemia virus type 1, which contains a peptide motif at the C-terminus
of nucleocapsid that is unique to primate T cell leukemia viruses and is responsible for
the exclusion of APOBEC3G from particles (272). Overall, it is clear that the inclusion
of the major structural components of CERV2 is warranted in an in vitro study of CERV2
restriction by APOBEC3. Thus, we constructed a consensus CERV2 Gag gene and
combined it with MLV Pol to make a chimeric GagPol (CERV2Gag-MLVPol). Due to
the requirement for MLV protease to process the CERV2 Gag in the maturation of
chimeric particles, a second version of CERV2 Gag (CERV2/MLV Gag) was synthesized
that replaced four amino residues on both sides of protease cleavage sites with those from
MLV (Figure 16A). Both chimeric GagPol proteins were functional in the context of
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VSV enveloped virions carrying a GFP reporter and, interestingly, intact CERV2 Gag
protease cleavage sites yielded particles with a titer that was two orders of magnitude
higher than particles containing cleavage sites from MLV Gag (Figure 16B).
To measure restriction by APOBEC3G, variable amounts of Myc-tagged human
APOBEC3G were co-transfected with VSVg, an MLV vector encoding a GFP reporter,
and either MLV GagPol or CERV2Gag-MLVPol. APOBEC3G was able to restrict
virions containing CERV2 Gag by up to approximately one order of magnitude, which
was similar to the restriction of particles carrying MLV Gag (Figure 16C). This result
suggests that APOBEC3G was, indeed, capable of restricting CERV2 replication. To
address a possible role for APOBEC3G in preventing CERV2 endogenization in the
human lineage, it was determined if human APOBEC3G was potentially more potent
against CERV2 than orthologues from species whose genomes were invaded by CERV2
family members. VSV-G enveloped CERV2Gag-MLVPol, MLV GagPol, or HIV
GagPol virions were generated in the presence of variable amounts of APOBEC3G from
human, chimpanzee, or rhesus macaque (Figure 17). Although human APOBEC3G was
more potent in terms of its restrictive effects compared to rhesus macaque APOBEC3G,
it was weaker than chimpanzee APOBEC3G. Furthermore, this order of APOBEC3G
potency was observed in the restriction of all three viruses tested. Therefore, a protection
of the human lineage from CERV2 cannot be ascribed to a restriction by APOBEC3G
that was potentially more powerful in human ancestors than it was in primates that were
unable to avoid CERV2 endogenization.
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Figure 16. A functional CERV2 Gag consensus and its sensitivity to human
APOBEC3G. A) Alignment of Gag amino acid sequences: CERV2 majority consensus
sequence, CERV2 majority consensus sequence with protease cleavage sites (marked
with vertical line) matching moloney MLV (CERV2/MLVGag), and moloney MLV. B)
VSV enveloped pseudotypes were generated by cotransfection with CNCG and MLV
GagPol or chimeras containing CERV2 Gag. The number of infectious units per mL
supernatant was measured by infection of 104 MDTF with a five-fold serial dilution. C)
MLV GagPol or CERV2Gag-MLVPol particles used to infect MDTF were prepared as
in (B) except with cotransfection of variable amounts of human APOBEC3G expression
plasmid. Empty vector was used to maintain the same amount of total transfected DNA.
The volumes used for infections were chosen to yield MOI 0.3 with APOBEC3G-minus
virus. The Gag carried of each virus is indicated.

79

80

Although CERV2 hypermutation only occurred in a dinucleotide context that was
indicative of APOBEC3G activity (i.e. GG), RhERV2 hypermutation also occurred in a
dinucleotide context that is targeted by several other APOBEC3 proteins (i.e. GA).
Therefore, we asked if human APOBEC proteins other than APOBEC3G are capable of
potently and specifically restricting CERV2, which would suggest that they could have
protected human ancestors from infection by CERV2. Restriction of CERV2 Gag virions
by most APOBEC proteins tested, though, was non-existent compared to APOBEC3G
(Figure 18). It should be noted that editing of ApoB mRNA by APOBEC1 involves the
APOBEC1 complementation factor (ACF) (273, 274) and perhaps inclusion of ACF
could alter the results presented here. In contrast to the lack of activity observed in most
APOBEC proteins tested, human APOBEC3F and APOBEC3A were able to moderately
restrict CERV2 infection (two- and three-fold, respectively) but none of the restriction
activities observed showed specificity for CERV2Gag virions over those containing
MLV Gag. Although the data presented here indicate that APOBEC3 proteins were
likely able to restrict CERV2 replication, there is no direct evidence that these restrictions
were responsible for protecting the human lineage from CERV2 infection.

81

Figure 17. Restriction of CERV2 Gag-containing virions by human, chimpanzee, or rhesus
macaque APOBEC3G. A) Titration of APOBEC3G was done as described in Figure 16C except
myc-tagged APOBEC3G genes from three different species were used as indicated. Additionally,
HIV virions were generated by cotransfection of VSVg, NL GagPol, and CSGW. B) Following
harvesting of the supernatent used for infections in (A), 293T cells transfected with MLV GagPol
were lysed in SDS-PAGE loading buffer for western blots probed with rabbit anti-MLV capsid or
mouse anti-Myc antibodies to the detect the 46kDa APOBEC3G proteins.
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Figure 18. Lack of potent restriction of CERV2Gag-MLVPol by human APOBEC proteins other
than APOBEC3G. A) The indicated human APOBECs were titrated as in Figure 17, except a
maximum of 600ng (rather than 300ng) APOBEC expression plasmid was used. B) Lysates from
MLV virus-producing cells used in (A) were used for western blot with a rabbit anti-MLV capsid
antibody.
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Chapter IV. The impact of APOBEC3 proteins on HIV-1 evolution in vitro

HIV-1 was used to investigate the potential impact of APOBEC3-induced
mutation on a replicating viral population. The interaction between HIV-1 and
APOBEC3 proteins is complex. Although its Vif protein protects HIV-1 from restriction
by human APOBEC3 proteins, hypermutated proviruses are abundant in infected patients
(192, 193, 197). It is currently unclear if these variants impose a significant burden to
overall fitness of the viral population, thus constituting a deleterious genetic load.
Another possibility, and one that is quite the opposite of the first, is that they can
contribute an increase in variability that could benefit a rapidly evolving population,
perhaps through recombination with fit viruses. Or, perhaps hypermutated proviruses
neither positively nor negatively affect HIV-1 evolution due to debilitating mutational
scars that have left their gene products entirely inactive and their genomes too
unrecognizable to even be packaged by competent viruses. To explore these possibilities,
we observed the accumulation of APOBEC3-induced diversity during HIV-1 replication
in vitro and the resulting viral populations were tested for their ability to evolve under
selective pressures.

Replication of HIV-1 delta Vif in permissive and semi-permissive cell lines
In order to assess the impact that APOBEC3-induced mutation has on a
replicating viral population in terms of both its overall fitness and adaptive potential,
HIV-1 or an HIV-1 lacking Vif expression (#Vif) were allowed to replicate in human T84

cell lines. Both viruses expressed GFP in place of NEF (to track the spread of virus
through the culture) and also contained mutations that prevented Vpr expression. The
latter was used to preempt a loss of Vpr that can occur during long-term culture and can
enhance virus replication (275). Two different cell lines, MT2 and CEMSS, both allowed
replication of #Vif virus but the Vif phenotype displayed in the two cell lines differed
(Figure 19). The replicative fitness of #Vif in CEMSS cells, as predicted by the
literature, was identical to that of the virus carrying intact Vif (Vif+) (152, 160). The
genetic screen that identified APOBEC3G as a host factor antagonized by Vif made use
of this permissive phenotype of CEMSS (152). Replication of #Vif in MT2 cells, on the
other hand, was restricted relative to Vif+ but not but not enough to prevent a spreading
infection that overtook the culture within five days- a two-day delay compared to Vif+.
A Partial restriction of #Vif replication has also been observed in activated PBMC and,
therefore, the #Vif phenotype observed in MT2 cells may be more realistic than that
displayed in restrictive cell lines that entirely extinguish #Vif replication (211).
The cytopathicity of the #Vif and Vif+ viruses also differed. To maintain the
MT2 culture infected with Vif+ (MT2/Vif+), fresh cells were added every three days
beginning four days post-infection to counteract frequent cell death (the ratio of fresh to
infected cells was approximately 1:4). In contrast, maintenance by the addition of
healthy cells was not necessary in MT2/#Vif cultures where cell death was rarely
observed. The relative robustness of MT2 cells infected with #Vif may be due to a lower
level of infectious virus in the culture. A titration of cell culture supernatant collected 15
days post-infection (dpi) was carried out by infecting MT2 cells overnight before the
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Figure 19. Replication of HIV with or without Vif in MT2 or CEMSS cells. A) 106 MT2 or
CEMSS cells were infected at MOI 0.001 with HIV-1 NL4.3/HxB/GFP delta Vpr with Vif (Vif+)
or deficient in Vif (#Vif). Aliquots of cells were fixed periodically for detection of GFP-positive
cells by FACs analysis. <0.1% GFP-positive (or <5 cells) is considered background based on
measurements of un-infected cells. B) Supernatants were collected from cultures described in (A)
at 15 dpi and titrated on 104 MT2 cells. Infections proceeded overnight before addition of
dextran sulfate, followed by fixation at two days post-infection. Infectious titer was derived from
the percentage of cells positive for GFP.
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addition of dextran sulfate to prevent multiple replication cycles. The titer of infectious
virus in supernatent from MT2/#Vif was 20-fold lower than that of MT2/Vif+ at 15 dpi
(Figure 19B). It should be noted that these infections included restriction by any
APOBEC3 proteins that may have been packaged into virions from the previous culture.
The behavior of infected CEMSS was different from that observed in infected
MT2. The infected CEMSS displayed frequent syncytia rather than cell death and these
effects were similar between CEMSS cultures infected with either Vif+ or #Vif. To
prevent fusions from occurring in the vast majority of cells, fresh CEMSS were
periodically added in equal amounts to both of the infected cultures. Still, after ten days
of replication, the CEMSS culture infected with Vif+ had a lower percentage of cells that
were GFP-positive compared to CEMSS infected with #Vif, which may have been a
reflection of weak GFP expression in unhealthy cells (Figure 19A). There was no
apparent difference, though, in the infectious titer of the supernatent in each culture at 15
dpi (Figure 19B). These results suggest that Vif may be toxic to the cells and could
contribute to the cytopathic effect of HIV replication in some cell types.
Replication of HIV-1 with or without Vif in restrictive cells presumably resulted
in viral populations that differed greatly in their sequence diversity due to APOBEC3induced mutation. It remained possible, though, that #Vif was able to replicate
efficiently in MT2 cells because of a weak penetration of APOBEC3 activity that allowed
the predominance of individual viruses entirely untouched by deamination over a
minority population of severely hypermutated viruses. To determine if APOBEC3induced sequence diversity could be observed following a period of continual viral
replication, #Vif or Vif+ were allowed to replicate in MT2 or CEMSS cells for 15 days
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before cells and supernatent were collected. Genomic DNA was purified from cells and
RNA was extracted from pelleted virions for cDNA synthesis. A 720-nucleotide locus
covering the polymerase domain of reverse transcriptase was amplified from both
proviral DNA in cellular genomes as well as cDNA made from virion-packaged viral
RNA. The resulting PCR products were cloned and twelve clones from each were
sequenced and compared to the wildtype sequence (Figure 20). All twelve proviral
sequences from MT2/#Vif contained varying degrees of mutations that were likely
caused by APOBEC3-catalyzed deamination (Figure 20A). These G to A substitutions in
GG or GA dinucleotide contexts varied in quantity from six to 38 per amplicon.
Surprisingly, APOBEC3-associated mutations were also detected in #Vif proviral DNA
from non-restrictive CEMSS cells, albeit at levels that were much lower than those
observed in #Vif proviral sequences amplified from MT2 cells (25 mutations in one
CEMSS/#Vif sequence and 1-12 mutations in six other clones out of 12 examined). This
suggests that levels of APOBEC3 proteins are present in CEMSS cells that are able to
accomplish a degree of catalytic deamination but are not sufficient to restrict virus
replication. In contrast, only a single G to A mutation within a GA or GG context was
found in proviral sequences from the MT2/Vif+ culture and none were found in
sequences from CEMSS/Vif+. In general, other types of mutations were found in a
minority of the sequences analyzed at a maximum of only one substitution per sequence.
An analysis of virion-packaged sequences revealed a different degree of GG to
AG and GA to AA mutations compared to those observed in proviruses (Figure 20B).
Although APOBEC3-induced mutations were observed again in the MT2/#Vif culture,
they were not found in every sequence (8/12) and, where present, there were only 2-10
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mutations per sequence. A decreased degree of hypermutation in packaged viral RNA
relative to integrated provirus may represent a purification of sequences that are either
not mutated or only moderately mutated by APOBEC3. Such selection could be
explained if severe hypermutation resulted in impaired LTR promoter function, the
degradation of RNAs that contain frequent stop codons by the nonsense-mediated decay
pathway, or the crippling of the RNA structures responsible for packaging into virions by
nucleocapsid. Interestingly, there were three virion sequences from MT2 cultures
infected with Vif+ virus and two from CEMSS infected with #Vif virus that contained a
small number of APOBEC3-associated mutations (1-3 mutations/sequence). In spite of
the small sample size of sequences in these analyses, it is clear that the population of
#Vif viruses in MT2 cells contained APOBEC3-driven diversity that was represented at
the level of viral genomic RNA. This suggests that an encounter of a viral genome with
APOBEC3 is not necessarily a dead end but, rather, hypermutated sequence may be
carried by virions during subsequent rounds of replication. Furthermore, it cannot be
concluded that either Vif+ virus replicating in #Vif-restricting cells or #Vif virus in nonrestrictive cells are entirely devoid of APOBEC3-induced mutation. The experiments
described below explored whether this varying degree of diversity can provide a benefit
or a burden to evolving viral populations.
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Figure 20. Detection of APOBEC3-induced mutations. A and B) DNA encoding the polymerase
domain of HIV reverse transcriptase was amplified, cloned, and sequenced. The number of
nucleotide substitutions relative to the wildtype sequence is shown for each sequence. Putative
APOBEC3-induced mutations are indicated as G to A changes that immediately proceeded a G or
A residue (blue or red, respectively) and all other nucleotide substitutions were pooled (grey).
Sequences were divided according to the inoculating virus (Vif+ or #Vif) and the cells in which it
replicated (MT2 or CEMSS). Templates for PCR were either cellular DNA preparations (A) or
cDNA derived from pelleted virions (B).
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Selection of drug resistance in Vif+ virus
We wished to determine if the potential for HIV-1 to acquire drug resistance
differed according to the degree of APOBEC3-driven diversity. First, #Vif or Vif+
viruses that had been grown in the absence of selection in MT2 cells (MT2/#Vif and
MT2/Vif+ viruses) were used to infect fresh MT2 cells at MOI 0.001. AZT, nevirapine,
or a combination of the two was added to the infected cultures on the following day
(Figure 22). The drugs were chosen because they are known to induce the emergence of
mutations that could potentially be caused by APOBEC3 activity (Table 1). AZT and
nevirapine were further selected because they offered a range of concentrations in which
virus spread in MT2 cells was inhibited but not entirely extinguished (Figure 21). In
contrast, inhibition with nelfinavir jumped from slight delays in viral spread to a
complete inhibition with only a two-fold change in drug concentration; while high
concentrations of 3TC, at best, caused a two-day delay in the complete spread of virus
through the culture.
Table 1. Drug resistance mutations that could result from APOBEC3
activity
Nevirapine
G190E
G196E
M230I

AZT
D67N
R211K

3TC
M41I
M184I
R211K

Nelfinavir
D30N
M46I
R57K
G73S

The amino acid substitutions listed are associated with resistance to the
indicated drug and are induced by GG to GA or GA to AA nucleotide
mutations. The NL4.3 GagPol sequence was used to determine the
dinucleotide context of the mutations. Based on data compiled in the Los
Alamos National Laboratory and Stanford University HIV Drug Resistance
Databases and other cited references (211, 276-294).
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Figure 21. Inhibition of spreading infection in MT2 cells by antiretroviral drugs. 106 MT2 cells
were infected overnight with Vif+ and then split into media containing nevirapine (A), AZT (B),
3TC (C), or nelfinavir (D) at the indicated concentrations. Cells were allowed to grow on 24-well
plates with a 1:5 passage into media containing fresh drug every four days. 100µL of cells were
fixed at several time-points for quantitation of GFP-expressing (or infected) cells.
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The Vif+ virus overtook the MT2 culture within 10 days in the presence of AZT
and it was also able to rapidly spread through a nevirapine-containing culture after an
initial decline in the number of infected cells (Figure 22A, B). Additionally, it took
MT2/Vif+ about a month to emerge under suppression with a combination of both drugs
(Figure 22C). In contrast, MT2/#Vif was not able to overcome any of these three
challenges. A titration of nevirapine or AZT in TZM cells during infection with the
putative drug-resistant viruses revealed that nevirapine resistance had, indeed, been
acquired by MT2/Vif+ during both single and dual-drug selections; but neither AZT
alone nor AZT in combination with nevirapine had induced any drug resistance (Figure
23). Inhibition with AZT at the chosen concentration was apparently only sufficient to
delay the rapid spread of Vif+, while nevirapine was potent enough to elicit the
emergence of drug resistance mutation(s). Amplification, cloning, and sequencing of
reverse transcriptase polymerase domain sequences from proviruses at the end of
selection with nevirapine revealed a variety of mutations associated with nevirapine
resistance in 8/10 sequences (Figure 24). One of these amino acid substitutions, M230I,
was the result of a GG to AG mutation. M230I was found in two sequences: one only
contained a single point mutation and the other contained 24 other APOBEC3-induced
amino acid mutations, including three stop codons. The hypermutant also contained
another predicted nevirapine resistance mutation, Y188C, which was not caused by a G
to A substitution and was shared by three other sequences. It is possible that during the
course of its escape, this individual accumulated one or both beneficial mutations before
a detrimental hypermutation by APOBEC3.
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The lack of drug resistance evolution in #Vif virus could be due to a continual
restriction by APOBEC3 proteins in MT2 cells during selection rather than a deleterious
effect of pre-existing genetic loads. Perhaps restriction, although not enough to prevent
the spread of #Vif through a culture that lacked drugs, severely decreased the odds of an
emergence by rare escape mutants. To address this, selection with nevirapine was
repeated using CEMSS cells where a lack of Vif did not result in lower replication
kinetics. In this experiment, viruses that were grown for 15 days without selection in
MT2 cells (termed MT2/Vif+ and MT2/#Vif viruses) as well as viruses grown in
CEMSS cells (termed CEMSS/Vif+ and CEMSS/#Vif viruses) were used to infect fresh
CEMSS at an equivalent MOI of 0.001. Nevirapine was added three days after infection
at a concentration that was capable of inhibiting a spreading infection in CEMSS cells
(Figure 25A). It should be noted that even in the absence of drug, MT2/#Vif displayed a
slower replication kinetic than the other three viruses- perhaps the effect of a deleterious
load of mutations (Figure 25B). Three weeks after infection, only CEMSS/Vif+ was able
to overcome inhibition by nevirapine; which, out of the four populations used to initiate
the selection, was the most likely to be devoid of any APOBEC3-induced mutations.
Therefore, these experiments demonstrate that immense diversity generated by
APOBEC3 in the absence of Vif does not necessarily make a productive contribution to
drug resistance evolution. It is possible that such potential can be outweighed by an
associated genetic load. Nevertheless, the occurrence of M230I in MT2/Vif+ following
selection with nevirapine, suggests that it is possible for low levels of APOBEC3-induced
mutation in Vif-positive viruses to productively contribute to evolution. It is worth
noting that in order to attain a low MOI before selection began, a bottleneck was imposed
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on the viral population and it is possible that this resulted in the loss of some potentially
beneficial APOBEC3-induced mutations. Perhaps the use of larger initial population
sizes prior to selection could allow the inclusion of broader diversity and, thus, reveal
greater evolutionary potentials.

Figure 22. Single and dual-drug selection in MT2 cells. Vif+ or #Vif viruses were grown in
MT2 cells for 15 days (Figure 19), and then used to infect fresh MT2 at MOI 0.01. One day after
infection, cells were split into plain media, 4µM nevirapine (A), 4µM AZT (B), or a combination
of 4µMAZT and 0.5µM nevirapine. Growth curves are plotted as percent infected cells
(expressing GFP) verses days post-infection.
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Figure 23. Evolution of nevirapine but not AZT resistance. TZM cells were infected at MOI 0.3
in media containing increasing concentrations of AZT (A and C) or nevirapine (B and D). Cells
were infected with either the Vif+ virus used to initiate selection experiments or resultant Vif+
viruses after spread through MT2 cells in the presence of the indicated drug (A and B) or drugs
(C and D). TZM infection was quantified two d.p.i. in relative luminescence units by a luciferase
activity assay. Inhibition relative to a minus-drug control (%) is plotted verses drug
concentration.
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Figure 24. Nevirapine resistance mutations. Following selection with 4µM nevirapine,
proviral sequences encoding the reverse transcriptase polymerase domain were amplified
from MT2 cellular DNA, cloned and sequenced. An alignment of the amino acid
sequence from 10 clones and the wildtype NL4.3 sequence is shown. Primer-binding
sites, including the first six codons of reverse transcriptase, were excluded. Sequences
with common mutations were ordered together. Amino acid changes predicted to confer
a decrease in sensitivity to nevirapine are marked with boxes (286, 287, 290, 291, 293,
294) and one of these (marked in blue) was caused by a G to A mutation in a GG
dinucleotide context.
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Figure 25. Selection with Nevirapine in CEMSS cells. A) Titration of nevirapine in infected
CEMSS was done as described in Figure 21 for drug titrations in MT2 cells. B and C) Vif+ or
#Vif grown 15 days in MT2 or CEMSS cells were used to infect CEMSS cells at MOI 0.001.
Three days later, cells were split into plain media (B) or media containing 500nM nevirapine (C).
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Selection of an escape mutant using patient plasma with neutralizing activity
In addition to in vitro drug-resistance evolution experiments, we also attempted to
evolve escape mutants under selection by antibodies present in broadly neutralizing sera.
Aside from providing a further examination of the evolutionary potential of APOBEC3mutated viruses, this type of selection experiment could also potentially identify novel
antigens targeted by neutralizing antibodies or more general determinants of
neutralization sensitivity. Selective pressure was imposed by blood plasma containing
broadly neutralizing activity that was taken from an HIV-1 infected, untreated individual
with long-term low levels of viremia (i.e. a long-term non-progressor) (295). For this
experiment, Vif+ virus was grown in MT2 cells and, therefore, only trace levels of
APOBEC3-induced mutations were expected. One day after infection at MOI 0.001,
MT2 cells were split into varying dilutions of neutralizing plasma. Every four days,
cultures were split 1:5 into media containing fresh plasma. A 1:20 dilution of the plasma
was initially able to prevent detectable virus replication for one week. Then, a steady
spreading infection was apparent over an additional one-week period before a plateau
persisted with 3-4% of the cells infected (Figure 26A). The resulting virus was titrated
and used in a second round of selection alongside the original virus stock (Figure 26B).
In spite of a slight fitness disadvantage, the selected virus was far less susceptible to
neutralization than its un-selected counterpart and after approximately two weeks of
additional selection, cells and supernatent were harvested for further analysis.
A titration of the patient plasma in a single-cycle infection demonstrated that two
rounds of selection had produced a virus with decreased sensitivity to the plasma’s
neutralization activity (Figure 27A). Envelope sequences were amplified from cellular
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DNA and ten clones were sequenced in order to identify putative escape mutations. A
point mutation in variable loop three (V3) of GP120, K306E, was common to all
sequenced clones (Figure 28). An envelope gene that did not contain any changes other
than K306E was subcloned into the parental virus and a titration of neutralizing plasma
demonstrated that this single mutation entirely recapitulated the decreased sensitivity
observed in the bulk population of passaged virus (Figure 27A).
The V3 loop has previously been identified as a target of neutralizing antibody
binding, but mutations to the V3 loop have also been implicated in conformational
changes that shift the general neutralization sensitivity of GP120. Specifically, a gain of
positive charges, particularly in residues 306 and 320, are thought to “open” the
conformation of GP120, which allows a shift in co-receptor usage from CCR5 to
CXCR4; but this conformational change is thought to also render the virus more
neutralization sensitive (54, 55). Here, the starting virus was X4-tropic and it is possible
that the K306E is not a specific antigen binding-site mutation that emerged due to escape
from recognition by a particular antibody, but rather it may have caused a conformational
change that was generally protective against a variety of antibodies. Although MT2 cells
do not express CCR5, K306E was still tested for its ability to utilize it as a co-receptor to
determine if the virus collaterally gained dual-tropism during neutralization escape.
Infection of CHO cells expressing a humanized cyclin-T (to allow HIV transcription),
human CD4, and either human CCR5 or human CXCR4 (259) showed that K306E was
still only X4-tropic (Figure 27B). Nevertheless, the emergence of a residue associated
with R5-tropism during neutralizing antibody escape, supports a model in which residues
associated with X4-tropism are inherently more neutralization sensitive.
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Figure 26. Selection using patient blood plasma with virus-neutralizing activity. A) MT2 cells
were infected with clonal Vif+ virus at MOI 0.001. The following day, infected cells were split
into plain media, or two-fold serial dilutions of patient plasma. Fresh plasma was added at the
same dilution when cells were split every four days. B) Second Passage. MT2 cells were
infected with virus selected in a 1:20 dilution of plasma (from A) or the same virus used to
initiate the first passage, both at MOI 0.001. The next day, both infection were split into plain
media or media containing a 1:20 patient blood plasma dilution.
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Figure 27. Escape mutants show decreased sensitivity to neutralization and remain X4-tropic. A)
HIV-1 used to initiate plasma selection (wt), virus resulting from two rounds of selection with a
1:20 dilution of plasma (post-selection), or virus containing a lysine to glutamate mutation at
envelope residue 306 (K306E) were used to infect TZM cells in the presence of neutralizing
plasma at the indicated dilutions. As was done for drug titrations in TZM cells, infection was
quantified two d.p.i. in relative luminescence units by a luciferase activity assay. Inhibition
relative to a minus-plasma control (%) is plotted verses plasma dilution. B) HIV-1 GFP
containing the R5-tropic YU2 envelope, the X4-tropic HXB-2 envelope, or HXB-2 envelope with
the K306E mutation was used to infect 104 HIV-1 permissive CHO cell lines expressing either
human CCR5 or human CXCR4. An average of two infections is shown for each.
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Figure 28. A V3 loop mutation was fixed into viral population during selection by neutralizing
plasma. Proviral envelope sequences amplified from MT2 cells after two rounds of selection in
neutralizing plasma were aligned with a confirmed wildtype HIV-1 HXB envelope sequence.
Blue lines mark the boundaries of the V3 loop and the K306E mutation is indicated with an
asterisk.
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Chapter V. Identification of the CERV2 cell surface receptor

While it remains possible that, as a means of defense, APOBEC3 proteins were
able to assault CERV1 and CERV2, the exploitation of other host factors by these viruses
would have been crucial to their successful infection of primate ancestors. In order to
bind and enter cells, CERV1 and CERV2 had to hijack host proteins that normally reside
on the cell surface to perform a task for the host. It is likely that the identity of these
receptors determined the types of cells that CERV1 and CERV2 were able to enter and,
perhaps, even the range of species they were capable of infecting. Therefore, to
understand the ancient inter-species transmissions and endogenizations of CERV1 and
CERV2, it is necessary to identify their cell-surface receptors.
In order to study the host range and receptor usage of CERV1 and CERV2 during
the time that they replicated, we constructed consensus envelope genes from both virus
families. Figure 29 shows an alignment of CERV2, RhERV2, and CERV1 consensus
envelopes with moloney MLV envelope. As is common for gammaretroviral envelopes,
a high degree of conservation was observed in the transmembrane protein (TM also
known as p12E) compared to a divergent surface protein (SU also know as gp70). As
expected, sequences were especially divergent in the regions that are responsible for
receptor binding in MLV (variable regions A and B); with the exception of CERV2 and
RhERV2, whose conservation in these regions may predict a common receptor usage.
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Figure 29. Clustal alignment of envelope protein sequences. Majority consensus
sequences of CERV2 envelope, RhERV2 envelopes A and B, and CERV1 envelope are
aligned with the moloney murine leukemia virus (moMLV) ecotropic envelope. The first
and last residues of the mature surface protein (SU or gp70) and transmembrane protein
(TM or p12E) are marked with red and blue asterisks, respectively. Proceeding SU is the
cleaved signal peptide and following TM is the R-peptide (or p2E). Variable regions A
and B are indicated by brackets according to those defined for MLV envelopes.
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Using CERV2 enveloped MLV pseudotypes carrying a GFP reporter (MLVGFP), it was determined that the consensus CERV2 envelope was functional (Figure
30A). Furthermore, it displayed a broad species tropism in that it supported infection of
human, chimpanzee, rhesus macaque, African green monkey, owl monkey, dog, rat, and
mouse cell lines. The permissivity of HeLa cells for CERV2 infection validated the use
of a HeLa cDNA library in a genetic screen for a CERV2 receptor, while the nonpermissive CHO-PGSA cells provided a negative background in which to perform such a
screen. CERV1 enveloped MLV particles were also able to infect both human and rhesus
macaque cells, but their low infectious titer prevented any practical genetic screen for a
CERV1 receptor (Figure 30C). Importantly, the ability of CERV1 and CERV2
enveloped particles to infect human cells already argues against the notion that the
absence of functional receptors protected the human lineage from CERV1 and CERV2
infection.
In order to identify the receptor used by CERV2 during the time of its exogenous
replication, a HeLa cDNA cell expression library was screened using particles that
carried the resurrected CERV2 envelope. First, VSV-G enveloped MLV particles were
used to stably transduce CHO-PGSA cells, which are normally resistant to CERV2
infection, with the HeLa cDNA library. The cDNA was delivered with an MLV vector
and 3’ to the cloning site, an internal ribosomal entry site (IRES) drove the expression of
a zeocin resistance gene. Transduction with the cDNA library was done in 20 parallel
pools of 2X105 cells at an MOI of 0.5. Following zeocin selection, 105 cells from each
PGSA cell expression library were challenged in duplicate with CERV2-enveloped
virions carrying a neomycin-resistant gene. This was done at a maximal MOI (3.5) to
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insure redundant coverage of every transduced PGSA clone. All but one of the forty
independent infections yielded neomycin-resistant colonies ranging in number from one
to twenty-four (Table 2). The colonies were pooled into 20 separate groups according to
the 20 initial cell expression sub-libraries. Each of these neomycin-resistant pools was
challenged independently with CERV2-enveloped virions carrying a hygromycinresistant gene. Numerous hygromycin resistant cells readily grew out of three of the
twenty pools. When challenged with CERV2-enveloped MLV virions that carried a
DsRED reporter gene, the hygromycin-resistant cells displayed a 100-fold increase in
permissivity relative to unmanipulated CHO-PGSA cells. Furthermore, this increase in
CERV2 permissivity occurred without a change in resistance to amphotropic MLV
infection (Figure 30B).
PCR amplification was performed using genomic DNA from the three PGSA cell
lines permissive to CERV2 infection (Figure 30D). To amplify the transduced gene(s),
primers were designed to bind sequences flanking the cloning site in the vector used to
deliver the HeLa cDNA library. A 1.7kb PCR product, which was not amplified when
DNA from unmanipulated PGSA was used, was cloned from all three cell lines and
identified by sequence homology to encode human copper transport protein 1 (CTR1)
(296). By comparison to database cDNA sequence, it was clear that all three clones were
missing the same number nucleotides from the end of the 5’ untranslated region,
implying that the three copies of Ctr1 isolated independently in the screen represented a
single molecular clone in the cDNA library that was transduced into PGSA cells three
independent times, each in a separate pool of starting PGSA cells.
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Table 2. Number of neomycin-resistant colonies
from CERV2-challenged CHO-PGSA cell
expression libraries.

Neomycin selection was applied following challenge with
CERV2 enveloped MLV virions. Results from two
replicate infections of each pool are shown.

In order to confirm that CTR1 expression was sufficient to confer CERV2
sensitivity to CHO-PGSA cells, the coding region was stably transduced into both PGSA
and the parental CHO cell line. The Ctr1 open reading frame was amplified using a
plasmid containing Ctr1 cDNA and the product was cloned into an MLV vector. VSV-G
enveloped MLV particles were used to transduce CHO and CHO-PGSA with both the
CTR1 open reading frame and a neomycin resistance gene. Indeed, expression of CTR1
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in both CHO and CHO-PGSA cells resulted in permissivity to CERV2 enveloped MLV
(Figures 30B,C). Expression of human CTR1 also made CHO cells permissive to an
MLV pseudotype carrying a consensus envelope from the CERV2 homologue in the
rhesus macaque genome (RhERV2). In contrast, transduction of human CTR1 did make
CHO cells permissive to CERV1, MPMV, GALV, or amphotropic MLV enveloped
virions, providing evidence that human CTR1 specifically enhances sensitivity to
CERV2.
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Figure 30. Human CTR-1 is sufficient to confer permissivity to CERV2 env mediated
entry in hamster cells. A) 50!L of CERV2-enveloped MLV particles carrying a GFP
reporter were used to infect 104 cells. Cell lines from a variety of species were usedhuman (293T, Hela), chimpanzee (PTSF), rhesus macaque (FRHK), African green
monkey (COS7), owl monkey (OMK), dog (D17), cat (CRFK), pig (PK15), rat (Rat2),
mouse (MDTF), and hamster (PGSA). Cells were analyzed by FACS two days after
infection. B) Following two rounds of selection with CERV2 enveloped MLV
pseudotypes, cells from three separate pools of cDNA library transduced CHO-PGSA
were tested for CERV2 permissivity compared to un-manipulated cells. MLV particles
carrying the indicated envelope and DsRED reporter construct were used to infect cells as
in A. CHO-PGSA stably transduced with human CTR1 were included in subsequent
replicates. C) CHO, CHO stably transduced with human CTR1, 293T, and FRHK were
infected as in A and B with MLV-GFP reporter virus pseudotyped with the indicated
envelope. D) DNA from three different CHO-PGSA cell lines, shown in (B) to be
permissive to CERV2, or unmanipulated CHO-PGSA were used in PCRs with primers
designed to amplify transduced HeLa cDNAs. PCR products were resolved on an
agarose gel. A 1.7kb product (indicated with an arrow) was common to PCRs from all
cell lines except unmanipulated CHO-PGSA.
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CERV2 entry into primate cells requires CTR1 and occurs at the plasma
membrane
Next, we asked if CTR1 is necessary in human cells for CERV2 infection. Two
different human cells lines were transfected twice with an siRNA pool targeting the
human Ctr1 open reading frame or luciferase siRNA and then re-plated for infection.
CTR1 siRNA pool was validated independently by knockdown of tagged CTR1
ectopically expressed in 293T cells (Figure 31A). Transfection of siRNAs against CTR1
reduced CERV2 infection by up to three-fold compared to cells transfected with control
siRNA, while susceptibility to amphotropic or VSV-G enveloped MLV was unaffected
(Figure 31B). To further demonstrate the necessity of CTR1 in CERV2 infections, we
tested whether its normal ligand, copper, is capable of inhibiting its function as a viral
receptor. Copper II chloride treatment did in fact cause a dose-dependent decrease in
HeLa infection that was specific for CERV2 enveloped virions (Figure 31C).
It has been shown that ectopically expressed CTR1 is endocytosed in response to
increased copper concentrations (297). In order to ask whether endocytosis, followed by
lysosomal maturation is involved in CERV2 entry, we determined if CERV2 infection is
pH-dependent. Pre-treatment and infection in the presence of either ammonium chloride
or the lysosomal maturation inhibitor, bafilomycin-A demonstrated in CHO-hCTR1 and
TE671 that infection by CERV2 enveloped MLV is a pH-independent event (Figure 32).
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Figure 31. CTR1 is necessary for CERV2 infection in human cells. A and B) 293T or HT1080
cells were transfected twice with an siRNA pool targeting CTR1 or luciferase siRNA before
seeding for infection with MLV-GFP carrying CERV2 or amphotropic envelope. Separately,
293T cells were co-transfected with plasmid expressing human CTR1 with an N-terminal HA tag.
Western blots from these cells are shown in A. Glycosylated forms of CTR1 can be observed
above the un-glycosylated protein (298-300). C) HeLa cells were incubated for 2 hours in CuCl2
before infection at the same CuCl2 concentration with the indicated MLV-GFP pseudotype. After
overnight incubation, cells were washed with fresh media and FACs analysis was completed 2
days after infection.
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Figure 32. CERV2 entry is pH-independent. TE671 (A) or CHO-huCTR1 (B) cells were
infected by CERV2, amphotropic, or VSV enveloped MLV-GFP +/- 30mM NH4Cl or 25nM
bafilomycin A following a two-hour pre-incubation under the same condition. After 3 hours of
infection, virus was removed and cells were incubated for an additional 2 hours in fresh media
with 30mM NH4Cl or 25nM bafilomycin A before replacement with plain media.
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Figure 33. Human CTR1 promotes binding of CERV2 particles to CHO cells. MLV GagGFP particles with or without CERV2 envelope were bound to CHO or a CHOhumanCTR1 single-cell clone. After one hour, cells were washed, fixed, and stained with
DAPI for microscopy. In parallel, CERV2 particle binding was also done in the presence
of CuCl2 following a CuCl2 pre-incubation. Images of CERV2 particles bound to each of
the cell types are shown including a merge of fluorescence with phase contrast. For
quantitation, 15 cells from each condition were chosen at random and the number of GFP
particles per cell was counted. The mean is indicated by a bar.
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CTR1 induces binding of CERV2 to the plasma membrane
To visualize virus attachment to target cells, an MLV Gag was used that carried a
C-terminal GFP fusion. Plasmid encoding the MLV Gag-GFP was transfected either
alone or with plasmid expressing the CERV2 envelope. This resulted in the production
of GFP-labeled virions that either carried CERV2 envelope or lacked an envelope
glycoprotein. Particles were bound to CHO cells or a CHO single-cell clone expressing
human CTR1 by applying un-concentrated supernatent at 4°C. Following a one-hour
incubation with the labeled virions, cells were washed three times and then fixed for
microscopy. Binding of CERV2 enveloped virions to unmanipulated CHO cells, in terms
of the average number of GFP foci per cell, was seen only at a very low level- lower even
than non-specific binding by particles lacking envelope glycoprotein (Figure 33B). On
the other hand, numerous CERV2 enveloped particles were bound to CHO-CTR1 cells
(Figures 33A, B). There were four times more CERV2 particles bound to CHO-CTR1
compared to CHO, and expression of human CTR1 did not have an effect on the binding
of non-enveloped virions. This demonstrates that human CTR1 is able to confer CHO
cells with the ability to bind CERV2 virions.
To further demonstrate that CTR1 is the cellular receptor for CERV2, we asked if
excessive copper decreases virion binding to cells (Figure 33B). CHO or CHO-CTR1
cells were pre-treated with 20!M CuCl2 followed by binding with CERV2-enveloped
GFP-labeled virions in the presence of 20uM CuCl2. Treatment with CuCl2 caused an
approximately two-fold decrease in the average number of CERV2 virions bound to
CHO-CTR1. This effect was modest compared to the 10-fold effect that 20uM CuCl2 had
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on HeLa infection. Therefore, it is likely that the binding defect does not entirely explain
the effect that copper treatment has on CERV2 infection and, perhaps, excessive copper
can also perturb events downstream of CTR1 binding.

Genetic determinants of CTR1 receptor function
To determine if the use of CTR1 by CERV2 is directly related to its cellular
function, mutants that have been previously shown to be deficient in copper transport
were tested for viral receptor function. Two CTR1 mutants with single amino acid
changes that were previously shown to have an effect on the rate of copper uptake were
included: M81I and Y156A (301). A third included point mutation, C189S, has been
shown to decrease CTR1 trimer stability (298). None of these point mutations affected
the ability of human CTR1 to serve as a CERV2 receptor (Figure 34B). Therefore, the
ability of CTR1 to serve as a receptor for CERV2 can be uncoupled from its copper
transport function.
Next, we sought to identify the genetic determinants of CTR1 viral receptor
function that render hamster cells non-permissive, and human cells permissive to CERV2
infection. Stable transduction of CHO cells with hamster CTR1 did not confer CERV2
permissivity, suggesting that the lack of CERV2 infection in unmanipulated CHO cells
was not merely due to low endogenous CTR1 expression (Figure 34A). CTR1 has three
transmembrane domains with a 64 amino acid extracellular N-terminal domain and a
three amino acid extracellular loop (298, 299, 302). To investigate whether the Nterminal extracellular domain from human CTR1 is both sufficient to confer viral
receptor activity to hamster CTR1 and necessary for the viral receptor function of human
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CTR1, this domain was swapped between the human and hamster genes and the resulting
chimeras were transduced into CHO cells. CHO cells stably expressing a hamster CTR1
with the human N-terminal extracellular domain were as permissive to CERV2 as CHO
cells expressing the full-length human CTR1, whereas CHO cells expressing human
CTR1 with the hamster N-terminal extracellular domain were non-permissive to CERV2
(Figure 34A). A C-terminal HA tag was included with the human, hamster, and chimeric
CTR1 proteins and a western blot demonstrated that all four cell lines had comparable
levels of CTR1 expression (Figure 34A insert).
Alignment of CTR1 amino acid sequences from primates revealed a high degree
of conservation (Figure 35). CTR1 proteins from human and chimpanzee are identical
and, relative to this amino acid sequence, the rhesus macaque CTR1 has two amino acid
differences and the orangutan, only one. All three of these mutations are found within
the N-terminal area of the extracellular domain that precedes an essential MMMMPM
copper coordination motif (303). An alignment of CTR1 from a wide range of mammals,
frog, and zebrafish shows broad divergence in this 40 amino acid N-terminal region,
which is followed by a highly conserved sequence in the rest of the protein. Transduction
of CHO cells with either wildtype human CTR1 or a mutant with a 40 amino acid Nterminal truncation was able to induce CERV2 permissivity to a similar degree (Figure
34B). The ability of CERV2 to use the CTR1 truncation mutant as a receptor
demonstrated that the most divergent region of CTR1 is dispensable in its receptor
function. As was therefore expected, hamster CTR1 mutants that resembled human
CTR1 in the membrane proximal portion of the extracellular domain were competent as
CERV2 receptors. Specifically, stable expression of a hamster CTR1 that contained the
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R(53)N and Y(59)S mutations (numbered by homology to human CTR1) was able to
induce CERV2 susceptibility in CHO cells. Furthermore, the addition of three
methionines to form a MMMMXM motif improved the receptor function of the
R(53)N/Y(59)S hamster CTR1 mutant. Inversely, a three-methionine deletion in the
human CTR1 MMMMXM motif resulted in decreased receptor activity and the
N53R/S59Y human CTR1 double mutant did not display any receptor function in CHO
cells. An N-terminal HA tag was included in all CTR1 proteins tested and expression in
transduced CHO cells was confirmed by western blot and surface stains (Figure 34B
insert and Table 3). Both the human CTR1 mutant containing a three-methionine
deletion and the N53R/S59Y double mutant had lower expression levels in CHO cells
compared to the wildtype human CTR1. It is possible that these expression differences
partially explain their lack of receptor activity. Nevertheless, the gain of receptor
function induced by the reciprocal mutations in hamster CTR1 clearly demonstrates the
importance of these residues in CERV2 infection.
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Figure 34. Genetic determinants of CTR1 viral receptor function. A) CHO cell lines expressing
C-terminal HA tagged human CTR1 (Hu), hamster CTR1 (Ham) or N-terminal extracellular
domain swaps (Hu-Ham and Ham-Hu) were seeded for infection with MLV-GFP pseudotypes.
Expression of CTR1 was detected by "HA western blot, and the glycosylated band is shown to
the right. B) CHO cells expressing N-terminal HA tagged CTR1 were infected with CERV2
enveloped MLV-GFP or used for "HA western blot (shown on right). Mutations to human CTR1
(wt) or hamster CTR1 (hamster wt) are indicated including a deletion of 40 amino acids at the Nterminus (40del) of human CTR1, deletion of methionine residues 41-43 (3Mdel) in human
CTR1, or addition of three methionine residues at the orthologous position in hamster CTR1
(ham 3Madd).
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Table 3. Surface staining of CHO
cells expressing N-terminal HA
tagged CTR1.
CHO cell lines
MFI %cells +
wt human CTR1
161
62.5
40del
154
84.4
M81I
324
94.4
Y156A
107
41.2
C189S
339
27.9
3Mdel
109
37.5
S59Y
342
79.0
N53R/S59S
92
40.0
wt hamster CTR1
160
73.9
ham 3Madd
92
45.8
ham R(53)N
135
58.3
ham Y(59)S
153
63.3
ham R(53)N/Y(59)S
125
52.4
ham 3Madd/R(53)N/Y(59)S
203
78.0
LNCX2
9
1.2
wt human CTR1 unstained
3
0.5
Stains were done with a mouse "HA
monoclonal antibody and an AlexaFluor488
conjugated secondary antibody before
FACS analysis.
Mean fluorescence
intensity (MFI) of the entire population and
the %cells with fluorescence greater than
that of vector and unstained controls is
shown.
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Figure 35. Clustal alignment of CTR1 proteins. The MMMMXM copper-coordination motif is
marked by a copper colored box, transmembrane domains by blue boxes, and residues mutated
for the studies herein are indicated by asterisks. The hamster CTR1 sequence was determined by
cloning the gene from CHO cDNA. All other sequences were previously annotated in the NCBI
gene database or were collected by a TBLASTN search of the non-redundant nucleotide database.
Sequences from chimpanzee, rhesus macaque, horse, dog, platypus, and opossum are annotated in
the sequence database as predicted transcripts. In the case of dog CTR1, a start codon at a
position homologous to other species is lacking therefore a downstream hypothetical start codon
(proceeding a G nucleotide) is shown.
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Chapter VI. Discussion

The study of contemporary viruses can describe modern, but not necessarily
formative, interactions between host genes and pathogens. The existence of endogenous
retroviral relics in host genomes allows for explorations of host and retrovirus coevolution that are not limited to present day infectious agents. The work herein
endeavored to gather evidence for or against past encounters of host factors with viruses
that have not replicated exogenously for millions of years, but may have imposed positive
selection on primate genes. The peculiar absence of CERV1 and CERV2 from the
human genome made them intriguing subjects for such studies because restrictions to
their exogenous replication by antiviral proteins may have limited their host ranges or
even caused their extinction.
Our investigation began with TRIM5 and APOBEC3 proteins because their
ability to restrict modern MLV set a reasonable precedent for the hypothesis that they
were also capable of targeting archaic primate gammaretroviruses (109, 110, 160, 304).
Evidence argued against the role of TRIM5" proteins, though, in both the inactivation of
CERV1 and CERV2 and in broad restrictions to their cross-species transmissions.
Nearly all endogenous capsid N-terminal domains studied lacked sensitivity to TRIM5
proteins from a variety of primate species. RhERV2 capsids carrying an E91K mutation
were an exception to the general TRIM5 resistance displayed by all other endogenous
retroviral capsids. Virions carrying these particular RhERV2 capsids were restricted by
chimpanzee TRIM5" and marginally by human TRIM5". The abundance of 91K in
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RhERV2 capsids (~20%) and its complete absence in CERV2 suggests that TRIM5"
may have imposed a selective pressure that limited the cross-species transmission of
viruses carrying this particular mutation to the chimpanzee ancestor and/or imposed a
constraint on CERV2 capsid variability.
There are two possible caveats to this study. First, the inactivation of CERV1/2
viruses, and hence the end of any possible selective pressure imposed by these
retroviruses on TRIM5 genes, may have occurred early enough in evolutionary history to
allow genetic drift and/or further selection by more recent pathogens to cause a loss in
recognition of ancient capsids by TRIM5 proteins. In other words, neutral evolution or
positive selection imposed by viruses other than CERV1/2 may have caused TRIM5
proteins to lose CERV1/2 capsid recognition. Contrary to this argument, though, is the
high degree of functional conservation and sequence identity between human and
chimpanzee TRIM5": 97% by amino acid sequence. Since the replication of CERV1/2
occurred after the divergence of humans and chimpanzees six million years ago, any
recent changes in TRIM5 specificity caused by the rise and fall of species-specific
retroviruses should be reflected in the divergence of these two genes; but despite the
absence of CERV1/2 from the human genome and its presence in the chimpanzee,
TRIM5" remains heavily conserved in both sequence and functional terms in these two
species. Furthermore, there are polymorphisms that remain common to both the rhesus
macaque and the sooty mangabey despite geographic separation and eight million years
of divergence, which suggests that balancing selection has prevented primate TRIM5"
from significantly shifting during the last few million years (305). In short, it is likely
that the replication of CERV1/2 and their homologues is too recent relative TRIM5
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functional divergence for changes in TRIM5" specificity to pose a problem in the
experiments discussed here.
Second, it is possible that there are unknown determinants of TRIM sensitivity
that are outside of the N-terminal domain of capsid. This concern was especially
highlighted by the description of a chimeric MLV containing p12 and a complete capsid
protein of an ancestral CERV1 that was restricted by human and chimpanzee TRIM5"
(260). It seems unlikely that the inclusion of the CERV1 CA-CTD or the p12 domain
could affect TRIM5 sensitivity because all known determinants of TRIM5 and Fv1
sensitivity map to the CA-NTD (108-111, 113, 114), and cleavage from the p12 domain
is required for MLV CA to interact with TRIM5 and Fv1 (306). However, in order to
deal with the possibility that there is an unknown determinant of TRIM5 recognition in
the capsid C-terminal domain, ancestral and consensus CERV1 full-length capsids were
used to confirm that chimeras carrying CERV1 capsid are resistant to TRIM5. Thus, this
result strongly supports the notion that TRIM5" proteins did not restrict CERV1 and it
also validates our experimental strategy for testing a broader range of CA-NTDs for
TRIM5 sensitivity.
Although it appears that TRIM5 proteins did not have an impact on CERV1 and
CERV2 replication, evidence does suggest that these viruses encountered APOBEC3
family member in both the chimpanzee and the rhesus macaque. This is evidenced by a
large number of G to A changes that occurred in dinucleotide contexts that are indicative
of modern APOBEC3 proteins. A disproportionate number of GG to AG mutations
compared to other G to A mutations was documented in CERV1, CERV2, RhERV1a,
RhERV2 and an excess of GA to AA mutations were also observed in individual
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RhERV2 proviruses. It is intriguing that RhERV2, unlike the other groups studied,
displayed two distinct dinucleotide biases: both GG to AG and GA to AA mutations on
separate proviruses. It is unlikely that these two mutagenic activities were separated
temporally because the proviruses in which they were found are not separated into two
phylogentically distinct groups. Rather, it is likely that RhERV2 was simultaneously
subjected to the action of at least two different deaminases. Indeed, modern rhesus
APOBEC3F and APOBEC3H are highly active relative to their human orthologues,
suggesting that they may be responsible for the abundant GA to AA mutations found in
RhERV2 (155-158).
Several analyses were completed in order to confirm that the excessive G to A
mutations in GG or GA dinucleotides were caused by APOBEC3-catalyzed deamination.
By removing CG dinucleotides from our analyses, we confirmed that the GG to AG
mutations observed were not due to spontaneous deamination at methylated CG islands in
the context of CGG trinucleotides. Some of the G to A mutations that were common to
multiple proviruses may have been due to amplification of a relatively small number of G
to A changes from founder viruses. It is unlikely, though, that the GG to AG changes
would be selectively amplified over other mutations because these changes did not confer
any fitness advantage MLV chimeras containing CERV1/2 CA-NTDs. To confirm that
the dinucleotide biases observed extend outside of capsid, many of the results were
corroborated by examining mutational biases in envelopes that were linked to the capsids
analyzed. Cases in which the bias in the G to A mutations was not consistent between a
capsid and a linked envelope could be explained by (i) stochastic variation in the small
numbers of capsid G to A mutations in th relatively short CA-NTD sequence (~400nt) (ii)
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variation in the mutation frequency (including 5’ to 3’ gradients) across individual
proviruses (iii) recombination between hypermutated and intact proviruses prior to or
during germline invasion, and/or (iv) high degrees of general sequence diversity in some
viral genes that may mask low frequency APOBEC3-mediated editing.
Modern APOBEC3G is known to induce GG to AG mutations but it remained
possible that an un-characterized cytidine deaminase activity was responsible for these
mutagenic events in CERV1 and CERV2. Furthermore, direct evidence that the editing
observed in these viruses translated to an observable restriction was lacking. To address
this, it was demonstrated in vitro that APOBEC3G can, in fact, restrict MLV chimeras
carrying CERV2 Gag. This supports the assertion that APOBEC3G was responsible for
GG to AG mutation found in CERV2 and that this activity was capable of restricting
CERV2 replication.
APOBEC3-induced mutations often crippled individual CERV1 and CERV2
viruses through the frequent introduction of stop codons and other deleterious
nonsynonomous changes. Especially given high frequency of stop codons generated by
GG to AG mutations, it is possible that APOBEC3 activity resulted in genetic loads that
had a damaging impact on the viral populations within each infected individual and
therefore may have also decreased the likelihood of intra- and interspecies transmissions.
Especially given the in vitro results confirming that APOBEC3G is able to restrict the
replication of virions containing CERV2 Gag , it is possible that APOBEC3 genes were
able to limit the species tropism of CERV1 and CERV2. Indeed, the species-specificity
of APOBEC3 recognition by lentiviral Vif proteins at least partially explains the species
tropism of modern lentiviruses; thus demonstrating the potential for APOBEC3 proteins
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to impose transmission barriers (156, 175, 307). in vitro APOBEC3G restriction assays,
though, were unable to provide direct evidence for a species-specific difference in
APOBEC3G potency against CERV2. Specifically, virions containing CERV2 Gag were
not more sensitive to human APOBEC3G compared to chimpanzee APOBEC3G, which
was apparently not potent enough to prevent CERV2 endogenization in the chimpanzee
ancestor.
It remains possible that the APOBEC3 activity described here was responsible for
terminating CERV1/2 replication. Again, deleterious non-synonymous mutations,
particularly stop codon formation, likely constituted a genetic load capable of impairing
the replication of a viral population within an infected host. An assertion that these
genetic loads caused CERV1/2 extinction may be premature, though, given that it is not
known if the level of mutations observed in CERV1/2 constitute a burden that was too
great for the viruses to overcome. It has long been theorized that recombination evolved,
in part, as a means to rid genomes of deleterious mutations, thus avoiding Muller’s
ratchet and preventing mutational meltdown (204-207). CERV1/2 may have been able to
cope with the heavy mutational burden observed here by continually producing fit viruses
through the recombination of mutated sequences. It should also be stated that the
proportion of proviruses in the infected chimpanzee and rhesus macaque ancestors that
were hypermutated would be over-represented if a selection existed against the
endogenization of fit viruses. Overall, although APOBEC3 activity likely explains the
inactivity of many individual CERV1/2 proviruses, it may or may not have contributed to
the extinction of exogenous CERV1/2.
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Further study of the CERV2 host range, as well as the limitations that hosts may
have imposed on it throughout history, required the identification of its cellular receptor.
By resurrecting a functional CERV2 envelope, we have determined that CERV2 used
CTR1 as its cell surface receptor during its exogenous replication millions of years ago.
Human CTR1 expression was sufficient to allow CERV2 virion binding and infection in
otherwise resistant hamster cells. In human cells, siRNAs directed against CTR1
inhibited CERV2 infection. The remaining infection in CTR1 knockdown cells could be
due to an incomplete knockdown but we cannot exclude the existence of a second
CERV2 receptor. The large effect that CuCl2 treatment had on CERV2 infection further
supports the importance of CTR1 in the infection of human cells. Although potent
inhibition by CuCl2 was clearly specific for the CERV2 receptor, the exact mechanism is
unclear. Down-regulation of ectopically expressed CTR1 from the cell surface in
response to CuCl2 treatment has been observed but it has also been shown that there is no
such effect on endogenously expressed CTR1, suggesting that inhibition of HeLa cell
infection is not necessarily explained by a lack of CTR1 cell surface expression (308310). Furthermore, the modesty of the binding defect caused by CuCl2 suggests that
perturbation of events downstream of initial binding to CTR1 may contribute to the
inhibitory effect that copper treatment had on infection. It is reasonable to speculate that
high amounts of copper flux at or near sites of virion binding may interfere with proper
virus attachment and/or fusion with the cell.
Several &-retroviruses use multi-transmembrane transport molecules as cellsurface receptors. Aside from their expression on the cell surface, no common property
of transport proteins has been shown to promote their ability to serve as receptors for
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viruses. In the case of CTR1, we demonstrated that viral receptor activity could be
uncoupled from its normal cellular function. Methionine residues are primarily
responsible for copper ion coordination during uptake through the membrane pore
formed by trimerized CTR1 (302, 303, 311). Mutation at methionine 81 within the first
transmembrane domain has been demonstrated to result in a two-fold decrease in the
Vmax of copper uptake (301). It has been suggested that tyrosine 156, found in the threeresidue extracellular loop, is responsible for positioning methionine residues at the
exterior opening of the transport pore through hydrogen bonding and mutation at this
residue results in a five-fold loss in copper uptake (301). The observation that point
mutants lacking each of these residues were able to serve as efficient viral receptors
supports the view that, as has been shown for the ecotropic MLV receptor, solute
transport function is not linked with virus reception (312).
The ability of CERV2 to use human CTR1 suggests that a species-specific
tropism during the period of exogenous CERV2 replication does not explain the absence
of CERV2 from the human genome. Additionally, human CTR1 is broadly expressed
(313), which is to be expected given the use of copper ions by crucial cellular enzymes
such as superoxide dismutase and cytochrome c oxidase. In particular, the expression of
CTR1 in the testes and ovaries implies that a lack of endogenization cannot be explained
by the absence of receptor expression in the germ line. Although we cannot rule out that
human CTR1 has lost CERV2 resistance during the time since exogenous CERV2
replication, this evolutionary course is unlikely given the perfect nucleotide sequence
identity between the extra-cellular regions of human and chimpanzee CTR1. Still, it
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remains possible that CTR1 allelic variability once included CERV2 resistance and
perhaps such polymorphisms were lost following the extinction of exogenous CERV2.
Interestingly, nearly all of the CTR1 sequence diversity is found in its N-terminal
extracellular domain and a 40 amino acid truncation mutant demonstrated that the area
containing nearly all of this diversity is dispensable for virus receptor function (Figures
34 and 35). That CERV2 only requires the extracellular domain’s most conserved
portion likely explains the permissivity of cells from diverse species. Furthermore, it is
possible that binding to this conserved region has been selected by multiple cross-species
transmission events that favored binding to a region in the new host that is similar to that
used by the virus in the previous host. For sequence variability to dictate the portion of
the receptor that was required for CERV2 infection, the virus would have to be capable of
altering its receptor usage when faced with unfavorable residues on CTR1. Observed
differences in receptor utilization that exist between closely related gammaretroviruses
suggests that they are, indeed, capable of rapidly changing the way they interact with a
single receptor in response to selective pressure imposed by the host. For example,
polytropic and xenotropic MLV bind to the same XPR1 domain and a few differences in
the receptor binding regions of xenotropic envelope enable it to also bind to a second
domain on XPR1 (78). Also, following the transmission FeLV-A to a new host, FeLV-B
or FeLV-C arise recurrently through either point mutations or recombination with
endogenous retroviruses, thus resulting in a swift change to a new receptor utilization
(86, 90).
Functional flexibility in the same extracellular region of CTR1 that is dispensable
for viral infection is not only suggested by diversity between species, but also by
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mutagenesis data. A human CTR1 mutant with a 34 amino acid N-terminal truncation
has been shown to entirely retain its copper transport ability (301). It was suggested that
this portion is responsible for receiving copper from extracellular copper chaperones that
are yet to be discovered, but the data presented here raises the question of whether CTR1
divergence could have been due to selective pressure imposed by retroviruses. The
extracellular copper-binding residues that are the most crucial to CTR1 function were
previously demonstrated to be the highly conserved MMMMXM motif (303), which
begins one residue before the end of a portion of CTR1 that is dispensable for CERV2
infection. In contrast to the high degree of conservation of this motif from human to
zebrafish, the hamster CTR1 has only an MPM in the orthologous position and, perhaps
for compensation, contains several unique copper-coordinating residues in other areas of
its extracellular domain (Figure 35). We have demonstrated that the three-methionine
deletion, along with point mutations at two other highly conserved residues, are
responsible for the resistance of hamster cells to CERV2 infection. It is tempting to
speculate that these changes represent an escape of the hamster lineage from a CERV2
relative. Whether or not this was the case, the divergence seen in the rest of the hamster
CTR1 N-terminal domain may compensate for its loss in the primary copper coordination
motif, thus representing an evolutionary hurdle that a primate would have had to
overcome to acquire CERV2 resistance by way of receptor evolution. The work
described here demonstrates that paleovirology has the potential to both identify novel
host factors that were usurped by ancient pathogens, as well as indicate the limitations
that hosts may have had in avoiding such exploitations by viral invaders.
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If the human ancestors were unable to avoid CERV2 infection through changes in
CTR1, then why were they spared from CERV2 endogenization? Again, we cannot rule
out a role for APOBEC3-mediated restriction in the protection of the human lineage from
both CERV1 and CERV2. But given the absence of clear species-specific differences in
CERV2 restriction potency, such a conclusion would fail to explain why APOBEC3 was
not also cable of protecting non-human primate ancestors from infection. One would
have to invoke a model in which resistance to CERV2 infection was evolved in ancient
primates through selection on APOBEC3 genes by CERV2 and the inactive proviruses in
the chimpanzee and rhesus macaque ancestors are the products of restrictions that
occurred following APOBEC3 adaptation. If replication competent CERV2 was
pathogenic, then a record of proviruses that integrated prior to the emergence of
APOBEC3-mediated hypermutation would be limited by selection against the
endogenization of active proviruses.
The above remarks must be stated with circumspection, though, given that the
presence of hypermutated proviruses does not necessarily predict that a given viral
population would be unable to replicate. If we may draw analogies between the effects
that APOBEC3 can have on distant retroviruses, the interactions that APOBEC3 proteins
have with HIV-1 suggest that a virus capable of overcoming restriction through the use of
an antagonist can still be subjected to hypermutation. Although an accumulation of
APOBEC3-mediated mutations can be observed in a portion of HIV-1 populations in vivo
and in vitro, the virus is still able to persist and avoid a mutational meltdown. In the in
vitro experiments presented here, hypermutation was observed in a vast majority of
sequences collected from deltaVif virus grown in restrictive cells. Importantly, the virus
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was able to persist in spite of the APOBEC3-induced genetic load that likely decreased
fitness and was not able to contribute to drug escape. In other words, heavy
hypermutation can impair viral evolution, but it does not necessarily provide a general
protection for the host or cause a mutational meltdown. Furthermore, in the case of Vif+
HIV-1, the presence of a low level of APOBEC3 activity did not appear to hinder drug
resistance evolution and may have even contributed to it.
Although HIV-1 and CERV1/2 are very distant viruses, it may be a recurrent
theme in APOBEC3 activity that hypermutation can occur even during the replication of
a virus that is able to persist. If this was the case for CERV1/2, then the endogenized
hypermutants may represent a small portion of the proviruses that has been biased toward
hypermutants by selection against the fixation of replication competent individuals.
Given that endogenization is a rare event and may exclude a highly fit majority, perhaps
the absence of CERV1/2 in the modern human genome does not necessarily suggest that
human ancestors were spared from exogenous CERV1/2. It may even be the case that
polymorphic CERV1/2 integrations were lost due to population bottlenecks during
human evolution. This has been suggested for a single HERV-K integration that is
identical in the gorilla and chimpanzee, while the orthologous locus in the human genome
contains an intact pre-integration site (314). It was argued that the integration occurred
prior to the divergence of the gorilla lineage from the human and chimpanzee and
remained polymorphic during the divergence of the human and chimpanzee lineages.
The allele carrying the integrated provirus then became fixed in the chimpanzee lineage
but, by chance, was lost from the human lineage as the allele containing the unperturbed
pre-integration site became fixed. The notion that endogenous retroviruses can remain
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polymorphic for long periods of time is supported by the observation that two HERV-K
insertions, HERV-K113 and 115, remain polymorphic in humans (315). If CERV1/2 did
infect human ancestors and endogenizations only occurred in a small proportion of
individuals, than one could imagine the neutral loss of entire groups of polymorphic
endogenous retroviruses to population bottlenecks.
Nevertheless, a definitive molecular explanation for the absence of CERV1/2
from the human genome may still exist. The CERV1 consensus envelope was not
sufficiently functional to perform a genetic screen, but if an improved envelope were to
be constructed then receptor identification would be worthwhile and could potentially
account for a limited CERV1 host range. Also, the tetherin restriction factor should be
considered. Although tetherin activity, unlike TRIM5", does not appear to depend on the
specific recognition of viral proteins, perhaps an unknown tetherin antagonist was able to
protect primate gammaretroviruses in a species-specific manner. Another potential
avenue of study ignored here is CERV1/2 LTR promoter function. Perhaps the CERV1/2
LTRs were unable to promote transcription in human ancestors. ZFP809 has been
identified as a murine zinc finger protein responsible for silencing the transcription of
MLV in embryonic stem cells through the bridging of transcriptional repressors to the
retroviral primer-binding site (316). Perhaps similar activities have guarded the human
lineage from gammaretroviruses. In general, as host genes continue to be identified that
either aid or inhibit retroviruses, the history of retroviral evolution may be further
explored and it is clear that paleovirology will continue to describe the formative and
longstanding evolutionary combat between retroviruses and their hosts.
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